



Deciphering osteoarthritis disease using multimodal
mass spectrometry methodologies
Citation for published version (APA):
Eveque, M. (2021). Deciphering osteoarthritis disease using multimodal mass spectrometry
methodologies. ProefschriftMaken. https://doi.org/10.26481/dis.20210226me





Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.




Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.





Deciphering osteoarthritis disease 






































































PhD thesis Maastricht University 
Deciphering osteoarthritis disease using multimodal mass spectrometry methodologies  
 
© Maxime Eveque, Maastricht, The Netherlands 2021 
The research reported in this dissertation was carried out at Maastricht Multimodal Molecular Imaging 
Institute (M4I), Universiteitssingel 50, 6229ER, Maastricht, The Netherlands.  
Cover design & layout: Maxime Eveque 




Deciphering osteoarthritis disease 











To obtain the degree of doctor at Maastricht University, 
on the authority of the Rector Magnificus 
Prof. dr. Rianne M. Letschert, 
in accordance with the decision of the Board of Deans, 
to be defended in public 



















Prof. dr. R.M.A. Heeren 
 
Co-Promotors 
Dr. B. Cillero-Pastor 
Dr. P. J. Emans  
  
Assessment Committee 
Prof. dr. M. Poeze, UM (Chairman) 
Prof. dr. M. Honing, UM  
Prof. dr. T.M. Hackeng, UM  
Prof. dr. M.H.B.J. Karperien, UT  





















This research was part of the M4I research program financially supported by the 
Dutch Province of Limburg through the LINK program. 
 
This research was also part of the collaboration between MUMC+ and M4I through 


















To my parents, sister, brother, niece and grandparents 







































































TABLE OF CONTENTS 
 
CHAPTER  1                       11 
1. General introduction                                            
 
1.1.  Rheumatic diseases 
1.2.  Mass spectrometry as a multimodal approach 
1.3.  Mass spectrometry imaging: applications to knee OA disease 
1.4.  Scope of the thesis 
 
CHAPTER 2             19 
2. Spatially resolved proteomics in osteoarthritis: state of the art and new perspectives  
 
2.1.  Abstract 
2.2.  Introduction 
2.3.  Mass spectrometry imaging 
2.3.1.  Matrix-assisted laser desorption/ionization mass spectrometry imaging of 
joint-derived tissues 
2.4.  Liquid extraction surface analysis 
2.5.  Histology-guided laser capture micro-dissection 
2.6.  MSI-guided proteomics 
2.7.  Mass cytometry and multiplexed ion beam imaging as targeted spatially-resolved 
proteomics 
2.8.  Conclusions and future perspectives 
 
CHAPTER 3            33 
3. Spatially resolved endogenous improved metabolite detection in human 
osteoarthritis cartilage by matrix assisted laser desorption ionization mass 
spectrometry imaging 
 
3.1.  Abstract 
3.2.  Introduction 
3.3.  Materials and methods 
3.4.  Results and discussion 
3.5.  Chapter conclusions 
 
CHAPTER 4            49 
4. Heterogeneity in lipid and protein cartilage profiles associated with human 




4.1.  Abstract 
4.2.  Introduction 
4.3.  Materials and methods 
4.4.  Results and discussion 
4.5.  Chapter conclusions 
 
CHAPTER 5             79 
5. Sox9 determines translational capacity during early chondrogenic differentiation by 
regulating expression of ribosome biogenesis factors and ribosomal proteins  
 
5.1.  Abstract 
5.2.  Introduction 
5.3.  Materials and methods 
5.4.  Results and discussion 
5.5.  Chapter conclusions 
 
CHAPTER 6                    107 
6. Valorization 
 
CHAPTER 7                   113 
7. General discussion 
 
7.1.  Sample preparation 
7.2.  The need of a multimodal approach 
7.3.  Molecular phenotypes of OA 
7.4.  Perspective of MSI in the OA field 
 




APPENDIX                            125 
References 



































































































































































   
Chapter 1 
13 
1. General introduction 
 
1.1. Rheumatic diseases 
 
Historically, Hippocrates associated the terms “Rheuma” and “catarrh” with a specific 
disease-causing process where “the mucus flux”, coming from the brain, travelled to 
various locations in the body such as the entrails and the joints.1 For the first time, 
Hippocrates also mentioned “the arthritic pain”, one of the common symptoms of 
rheumatic diseases. 
 
Rheumatic diseases are mainly characterized by pain and loss of motion or flexibility in 
one or several joints in the body. Within the current classification and response criteria, 
rheumatic diseases are associated with more than 100 different disorders. Among them, 
osteoarthritis (OA) is the most prevalent. 
 
OA is characterized by the progressive deterioration of articular cartilage from any joint, 
but occurs more often in knees, hands, hips, lower back, and neck. OA is the world’s 
oldest known disease, with evidence present in skeletons of dinosaurs.2 OA is also 
considered an age-related pathology3 and its prevalence varies depending on the joint 
under study and the characteristics of the study population.4 Many factors contribute to 
the development of the pathology including lack of exercise, obesity, genetic 
predisposition, gender, bone density, or any trauma affecting joints, such as post-
traumatic OA (PTOA).5 The multifactorial aspect of the pathology leads to different 
phenotypes within the OA population. However, all the phenotypes receive similar 
treatments, regardless of their potential biological differences, which results in inadequate 
therapy. Therefore, new patient stratification based on phenotypes is needed for 
personalized therapeutic strategies.   
 
Lately, several models for the classification of these phenotypes have been proposed.6, 7 In 
particular, the metabolic syndrome (MetS) phenotype is defined by the role of obesity and 
by chronic low-grade inflammation, which leads to systemic and local change during OA. 
8-10 MetS is a health disorder affecting 10–30% of the worldwide population with a 
prevalence of 59% in OA patients. 11 MetS is diagnosed when a patient has at least three of 
the following conditions: i) high blood pressure (≥130/≥85 mm Hg), ii) high blood glucose 
levels (≥110 mg/dL at fasting glucose), iii) high triglyceride levels (≥150 mg/dL), iv) low 
HDL-cholesterol (<40 mg/dL in men and <50 mg/dL in women), and v) a large waist 
circumference (>102 cm in men and >88 cm in women).12 MetS also increases the risk of 
developing other diseases such as obesity, type 2 diabetes mellitus (T2DM), hypertension 
or dyslipidemia.13,14 In particular, OA and T2DM frequently co-exist, and a higher 
prevalence of developing OA in T2DM patients has been shown.15-18 The T2DM disease is 




mechanisms underlying the pathological processes of the OA/T2DM phenotype is one of 
the goals of this thesis. 
 
Since rheumatic disease is a broad and complex disease, the following general 
introduction will focus exclusively on OA pathology. First, we will describe the knee and 
the different tissues involved in the structure of the joint. The knee is considered the most 
commonly affected area by OA21 and the cartilage from this joint has been the primary 
tissue used in the research presented in this thesis. Second, we will stress the importance 
of mass spectrometry technology with a focus on mass spectrometry imaging, which 
played a pivotal role in this thesis. 
 
The knee joint is constituted of cartilage, synovial membrane, synovial fluid (SF), 
subchondral bone and Hoffa’s fat pad (HFP) tissues:  
 
The cartilage tissue is composed of chondrocyte cells embedded in an extracellular matrix 
(ECM) mostly composed of collagen and proteoglycans,22 but also containing other, non-
collagenous, proteins and glycoproteins.23 All these components help to retain water 
within the ECM to maintain the mechanical properties of the cartilage.24 Moreover, the 
cartilage is composed of different layers: the superficial layer, the deep layer and the 
transitional layer. The superficial layer of the cartilage is in close contact with the synovial 
fluid and it is the only zone where articular cartilage progenitor cells have been found.25 
The deep layer remains closer to the subchondral bone. The superficial and the deep layers 
are separated by the transitional layer. 
 
The synovial membrane (or synovium) consists of two layers, the intima and subintima. 
The intima is a continuous surface-layer of cells, composed of macrophages and synovial 
fibroblasts that are embedded in a collagen and hyaluronan-matrix.26 The subintima is an 
underlying tissue that is composed of blood and lymphatic vessels. These two layers are 
separated by the intimal surfaces that contain a small amount of fluid. This fluid is usually 
rich in hyaluronan.27 The synovial membrane is only found in synovial joints and 
functions mainly to release the SF. 
 
SF is a hyaluronic acid-rich liquid released by the synovial membrane.28 It brings nutrients 
for chondrocyte metabolism in cartilage. SF also lubricates joints by using mostly 
proteoglycan-4 and hyaluronan.29 A major component of SF is proteins derived from 
plasma, although soluble molecules, like growth factors and cytokines are also present.30, 31  
 
The subchondral bone is usually the transition zone between calcified cartilage and the 
rigid skeleton.32 Cartilage and the rigid skeleton can also meet at a thin interface known as 
the cement line.33 The osteochondral junction, where the subchondral bone resides, is not 
completely understood; however, several studies have demonstrated the involvement of 




Finally, HFP tissue is an extra synovial structure mainly composed of adipocytes and 
connective tissue, containing collagen and glycosaminoglycans.36  
 
All these joint components described are affected during OA. The disease results mainly in 
cartilage degeneration, but also includes synovial membrane inflammation and changes in 
the subchondral bone.37, 38 Moreover, the inflammation of the synovial membrane leads to 
an elevated production of SF which produces joint swelling and pain.39 Finally, the HFP 
tissue is now recognized to play a role in the pathological process of OA. 40 The 
involvement of all these tissues makes OA as a complex and heterogeneous disease. The 
identification of biomarkers, both for diagnosis and prognosis of OA, remains essential to 
measure the different pathological processes linked to the disease. Nowadays, different –
omic approaches (transcriptomics, lipidomics, metabolomics, proteomics and glycomics) 
are employed to better understand the different pathological processes linked to OA and 
to improve treatment of the pathology based on the associated phenotypes we previously 
discussed.  
 
1.2. Mass spectrometry as a multimodal approach 
 
Mass spectrometry (MS) is an analytical technology used in many -omics based studies.41 
MS is a powerful, label-free analytical tool that can detect biomolecules (e.g., lipids, 
peptides, proteins, metabolites, and glycans) and can be used for many applications.42-44 A 
mass spectrometer contains three main elements: the ionization source, the analyzer, and 
the detector. The ionization source enables the desorption and ionization of analytes from 
the surface and transforms them into the gas phase as ions. These ions are then separated 
based on their mass-to-charge ratios (m/z) using an electric or magnetic field from one of 
the many types of mass analyzers. The detector will produce a signal in response to these 
ions. This signal can be transformed into a mass spectrum, which displays the relative 
abundance of detected ions as a function of their m/z values. MS provides different 
capabilities in terms of accuracy, sensitivity and high throughput depending on different 
instrument configurations.45 
 
Mass spectrometry imaging (MSI) is one of the major methodological developments in the 
mass spectrometry field. MSI investigates the distribution of a wide variety of 
biomolecules through in-situ analysis of tissue sections.46, 47 MSI analysis of biological 
samples became possible with the development of soft ionization techniques such as 
matrix assisted laser desorption/ionization (MALDI) and electrospray ionization (ESI). 
The first MALDI-MSI experiment was performed in the late 1990s.47 Since then, MALDI-
MSI has been established as a useful imaging tool in the clinical field, where the number of 





The ionization technique used in an MSI experiment also needs to be adapted according to 
the tissue type, the required spatial resolution and the targeted molecular class.48 For this 
purpose, MALDI remains the most versatile MSI technique since it allows the detection of 
a wide range of molecular classes and can be used for high spatial resolution experiments. 
49, 50 In a traditional MALDI-MSI experiment, a sample, often a tissue section, is placed on 
a glass slide or conductive surface. Then, a UV-absorbing matrix is applied to the sample 
surface to facilitate the desorption and ionization process. The UV laser is fired at 
predefined positions, or pixels, of the tissue. A mass spectrum is then collected at each of 
these measured positions/pixels on the sample. MALDI-MSI enables the selection of 
particular molecules or m/z peaks of interest to plot in a 2D heat map. These plots and heat 
maps display the distributions and relative intensities of molecules of interest within the 
tissue. 
 
1.3. Mass spectrometry imaging: applications to knee OA disease 
 
The application of MSI in the rheumatology field is recent, with only a few reports 
published so far. In the context of OA disease, MALDI also remains the most applicable 
ionization method used for imaging experiments, which is mainly due to the molecular 
composition of OA-affected tissues. MALDI-MSI has been applied to chondrocytes51 and 
mesenchymal stem cells52 to characterize the lipid profiles and lipid spatial distribution. 
Moreover, MALDI-MSI has been applied to the synovial membrane to spatially-resolve 
the protein/peptide distribution53 and on subchondral bone to image N-glycans.54 
MALDI-MSI is also applied to cartilage, which is helpful in distinguishing superficial and 
deep layers of the tissue. Another study demonstrated a specific distribution of fibronectin 
and cartilage oligomeric matrix proteins in the deep layer of OA human cartilage 
samples.55 A study conducted by Cillero-Pastor et al. using another imaging methodology 
such as time-of-flight (TOF) secondary ion mass spectrometry (SIMS), also demonstrated 
that lipids such as cholesterol accumulate in the superficial layer of cartilage during OA.56 
Cholesterol has a regulating role in growth plate chondrogenesis and skeletal 
development.57 
 
1.4. Scope of the thesis 
 
The work described in this thesis focuses on the development of mass spectrometry-based 
approaches to answer biological questions related to the OA pathology and subtyping. 
 
In chapter 2, we discussed the general principles of the bottom-up proteomics approach. 
We reviewed the recent studies applied to different tissues involved in OA disease based 
on this approach and provide new methods which are not fully applied by the OA 
community yet. We finally discussed the spatially resolved proteomics approach because 
we believe that the spatial distribution of the proteins within the tissues is critical to 




The spatial distribution of endogenous metabolites has never been resolved in OA 
cartilage tissue. That is the main reason why in chapter 3, we developed a sensitive 
approach to detect endogenous metabolites on human cartilage by MALDI-MSI. We 
showed that heat stabilization performed immediately after total knee replacement 
surgery is a critical point, mainly by slowing-down the degradation of metabolites. This 
chapter also described the optimized method we used to reveal a higher presence of 
endogenous metabolites in the superficial layer of the human cartilage tissue.  
 
In chapter 4, we described a multimodal MS approach which combined both label-free 
proteomics and MALDI-MSI methodologies. Our protocol was applied to samples of 
human cartilage and revealed distinct protein and lipid signatures between OA/T2DM- 
and OA/T2DM+ phenotypes. The MALDI-MSI approach also demonstrated lipid 
differences between the superficial and deep layers of the cartilage. Together, these results 
suggested the need to consider different OA phenotypes in order to provide more 
personalized therapies.  
 
The label-free proteomics strategy was combined with a transcriptomic approach in 
chapter 5, where we studied the role of the Sox9 gene during the early phase of 
chondrogenesis process in ATDC5 cells. The data presented show a connection between 
early Sox9 gene expression and ribosome biogenesis, in particular in terms of protein 
translational capacity. 
 
Finally, the valorization chapter (chapter 6) describes the main outcomes of this thesis that 
could be addressed in the future to further impact the field of the OA disease, with a 
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2. Spatially resolved proteomics in osteoarthritis human research: 




Osteoarthritis (OA) is one of the most common diseases worldwide caused by 
chronic degeneration of the joints. Its high prevalence and the involvement of several 
tissues define OA as a highly heterogeneous disease. New biological markers to 
evaluate the progression of the pathology and improve its prognosis are needed. 
Among all the different -omic strategies applied to OA, solution phase bottom-up 
proteomics has made an extensive contribution to the field of biomarker research. 
However, new technologies for protein analysis should be considered for a better 
understanding of the disease.  
 
This review focuses on complementary proteomic methodologies and new 
technologies for translational research of OA and other rheumatic pathologies, 
especially mass spectrometry imaging and protein imaging methods not applied by 




Osteoarthritis (OA) is an age-related joint disease and the most common rheumatic 
disease affecting 10 to 20% of people over 50 years old. 58 The disease is characterized 
by an alteration of the whole joint structure, including progressive cartilage 
degradation 22-24, synovial membrane inflammation 26, 27, and changes to the 
subchondral bone. 32-35 Moreover, the inflammation of the synovial membrane leads 
to an elevated production of synovial fluid (SF) which produces joint swelling and 
pain. 30, 31 Due to the complexity of the joints, OA remains thereby a heterogeneous 
disease. 
 
Nowadays, different –omic strategies are employed for discovery, characterization 
and quantification of biomarkers in order to improve prognosis and diagnosis. 59, 60 
In particular, proteomic strategies are increasingly applied to OA research and OA 
biomarker discovery. 61-63 
 
Proteins fulfill essential functions in cells. These include enzymatic reactions to 
produce energy, immunological response and/or cellular communication. The panel 
of expressed proteins in a given cell type or organism defines the term “proteome”. 
Contrary to the genome which is more static, the proteome is dynamic, making the 
comprehensive analysis more challenging. 64 Proteomic technologies focus on the 
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identification, quantification and/or characterization of proteins that are present in a 
sample using mass spectrometry (MS). 65 Proteomics provide information on protein 
identity and sequence, protein abundance, protein interactions, post-translational 
modifications (PTMs) and protein turnover. Although several methodologies are 
now available in the field, the bottom-up approach has been widely described and is 
now the most frequently used technique that allows high throughput analysis of 
complex samples. 66-68 The bottom-up approach relies on protein extraction prior 
separation using different methods such as isoelectric focusing (IEF) and sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). However, gel-free 
approaches are nowadays more frequently used. 69, 70 These approaches enable the 
reduction of the sample complexity and increase the proteome coverage. Proteins are 
then chemically processed by a reduction/alkylation step, before being 
enzymatically digested (commonly by trypsin 69 or LysC/trypsin 70) to finally get 
peptides. The peptides are subsequently separated by reversed-phase liquid 
chromatography (RP-LC) before entering the mass spectrometer. Tandem mass 
spectra (MS/MS or MS2) are finally matched against in silico spectra by a search 
engine, which assigns peptide sequences and infers the corresponding proteins. 68 
 
As example of recent studies, a pilot analysis conducted by Folkesson et al. 
investigated the difference in protein expression on cartilage between the tibial 
condyle and the meniscus from human knees. 71 The results showed similar subset of 
differentially abundant proteins but with different fold changes depending on the 
analytical method that was employed. For instance, dermatopontin has been 
quantified with a 15-fold change in the meniscus using data independent acquisition 
(DIA), whereas a 29-fold change was reported using data dependent acquisition 
(DDA). Another study performed on SF from OA patients identified potential 
biomarkers and drug targets such as the complement C1r and the dickkopf-related 
protein 2. 72 Proteomics has also been used on SW1353 chondrocyte-like cells to 
explore the effects and mechanisms of Astragaloside IV (ASG-IV), a reported drug 
which promotes rapid proliferation of these cells. Quantitative results suggested that 
extracellular matrix (ECM) signaling pathways were modulated by ASG-IV, 
indicating its key role in OA chondrocyte apoptosis. 73 Another study performed on 
the chondrocyte secretome reported the relationship between smoking and the 
development of OA. Nineteen proteins have been found to be altered by nicotine 
including several cytokines and proteases. 74 
 
Most of the bottom-up work comprehends the analysis of peptides with a 
mass/charge ratio (m/z) below 3 kDa, due to the use of trypsin as a gold standard for 
digestion. Although this configuration is well-established, most of the PTMs and 
proteoforms are not preserved. 75-77 Consequently, other approaches may be 
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considered. Middle-down and top-down strategies are two other techniques used in 
the proteomics field. The middle-down approach focuses on the analysis of middle 
range peptides with a molecular weight comprised between 3 kDa and 10 kDa 69, 
thanks to the use of other enzymes. On the other hand, the top-down approach 
employs MS to study intact proteins and their proteoforms. 78, 79 In the context of OA 
disease, both methods could be considered to improve the sequence coverage of OA-
related proteins such as collagens or to study specific PTMs such as phosphorylation. 
80 
 
The above-mentioned proteomic approaches have been also applied to study the 
interactome. The proteome becomes more complex when considering all the possible 
networks of physical and functional interactions between proteins but also with 
other biomolecules such as DNA, RNA, lipids and metabolites. 81-85 Protein cross-
linking coupled with mass spectrometry (XL-MS) provides a platform to freeze the 
transient interactions through the formation of covalent bonds. In this way XL-MS 
provides a vital insight into both the structure and organization of proteins. 86 
 
These previously described approaches allow protein analysis from whole tissue 
lysates or cell extracts. However, due to the importance of the cross-talk of the 
different joint tissues, the spatial location of proteins is critical, especially when 
tissues contain regions with diverse cell subpopulations. The study of tissue protein 
distribution defines a new area namely spatially resolved proteomics. In this review, 
we discuss how spatially resolved proteomics can be employed in the field of 
rheumatic pathologies and especially in OA. 
 
2.3. Mass Spectrometry imaging 
 
Mass spectrometry imaging (MSI) is a label free technology that allows the multiplex 
analysis of a broad variety of analytes in tissue sections such as proteins, peptides, 
lipids, drugs, and metabolites. 87 Usually, MSI spatial resolution ranges from nano- to 
micrometers depending primarily on the type of ionization technique employed. 88 
This approach can reliably indicate the specific molecular location within a tissue. 
MSI records a mass spectrum at every measured position (x and y coordinates) on 
the sample. Consequently, each mass spectrum reflects the local molecular 
composition at every coordinate. The m/z of interest can be then selected and plotted 
in a heat map to display their respective distribution and relative intensity. The tissue 
sections can optionally be stained after the imaging experiment with 
hematoxylin/eosin, alcian blue, or immunostained 89 before co-registration with the 
MSI data. 
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2.3.1 Matrix-assisted laser desorption/ionization mass spectrometry imaging of 
joint-derived tissues 
 
Among all the ionization techniques, matrix-assisted laser desorption/ionization 
(MALDI) is the most applicable method to the rheumatology field due to the 
molecular composition of OA-affected tissues. MALDI-based ionization imaging is 
the most versatile MSI platform that allows the in-situ detection of a large number of 
peptides and proteins. 
In a general MALDI-MSI workflow, tissue sections are placed on regular microscope 
or conductive glass slides and coated with a suitable matrix solution that assists in 
desorption and ionization of the analytes. During the experiment, the tissue is locally 
irradiated by a laser beam generating a mass spectrum for each measured position. 
MALDI-MSI has been applied in the past years to investigate joint tissues in 
rheumatic disorders. Mainly, specific MALDI-MSI protocols have been developed to 
explore the differences in the composition and distribution of peptides between 
healthy and OA tissues. In this workflow, trypsin is deposited directly on the tissue 
surface after performing washing steps and before matrix application. Once the 
peptide map is generated, direct MS/MS fragmentation of the detected peptides is 
carried out to identify the corresponding protein. This method offers the advantage 
of identifying proteins from tissues without separation and homogenization, while 
preserving the information on their spatial distribution. 90, 91 Using this methodology, 
the spatial distribution of well-known OA related peptides/proteins in cartilage has 
been previously reported. In this work, fibronectin peptides displayed a stronger 
intensity in OA cartilage compared to control tissues and were found to be more 
abundant in the deep areas of the cartilage. 55 Moreover, cartilage oligomeric matrix 
protein (COMP) peptides showed a similar spatial distribution as fibronectin. 
MALDI-MSI has also been employed to investigate the distribution of ECM proteins 
in young, old and OA equine cartilage. 92 In this work, peptides corresponding to 
COMP showed a higher expression in old equine samples compared to young and 
OA cartilage, whereas collectin-43 protein was specific to young cartilage. 
Recent advances in MS instrumentation have allowed improvements in terms of 
mass resolution, spatial resolution and acquisition time (Figure 2.1). As shown in the 
figure, high mass resolution mass spectrometry is required to differentiate between 
peptide ions (m/z 1004.4503 and m/z 1004.4817) that possess a different spatial 
distribution. 





Figure 2.1. Molecular distribution in human knee cartilage acquired at 30 μm on a MALDI-Orbitrap 
mass spectrometer. (A) Positive ion-mode images show the spatial distribution of peptides 
(m/z 1484.7247 and m/z 1140.5782). The color scale indicates the relative intensity. The m/z 1484.7247 is 
mainly distributed in the deep area of the cartilage while the m/z 1140.5782 shows homogeneous 
distribution within the tissue. The distribution of a lipid (m/z 703.5753) is also displayed with a specific 
distribution in the superficial area of the cartilage and has been identified as sphingomyelin 34:1 by 
tandem mass spectrometry. (B) Average peptide mass spectrum of human cartilage. MALDI-enabled 
Orbitrap Elite spectra showing the differentiation of two peptide ions (m/z 1004.4503 
and m/z 1004.4817) with differential spatial distribution. 
 
Differences in the composition and distribution of intact proteins have been 
investigated in synovial tissues with MALDI-MSI. 93 In this work, synovial samples 
of patients with rheumatoid arthritis (RA) and OA were compared and specific 
proteins were correlated with disease-associated synovial changes. Among them, 
defensins and S100 proteins were located in both synovial membrane layers, the 
subintima and the intima, and displayed a higher abundance in RA samples 
compared to OA. On the other hand, thymosin beta truncated proteins were 
differentially distributed across tissue layers, showing a higher intensity in the 
sublining layer of RA patients. Moreover, protein thymosin beta 4 was 
predominantly observed in the hypertrophic lining layer of OA and RA samples. In 
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this study, MALDI-MSI was applied for the first time to synovial tissue providing 
tissue-specific protein biomarker candidates of patients with RA and OA. 
 
Another MSI based-study performed on synovial membrane described a specific 
protein profile discriminating control from OA synovium tissues. 53 Interestingly, 
fibronectin-related peptides were mainly located in hypertrophic areas of OA 
synovial membranes, which are characterized by an increased tissue inflammation. 
As stated above, these peptides were also previously detected by MSI in OA 
cartilage. These findings suggest that fibronectin is a common feature in OA tissues 
(cartilage and synovium) and could be used as a potential biomarker to discriminate 
between healthy and OA related tissues using MALDI-MSI. 
 
Spatial peptide alterations have been recently reported in other musculoskeletal 
diseases by MSI such as in severely injured skeletal muscles in response to 
transplantation of autologous bone marrow mesenchymal stromal cells (MSC-TX). 94 
In this work, the pathophysiological muscle areas in primary traumatized and 
adjacent areas were analyzed and compared pointing out differential peptide 
distributions between groups. These results also demonstrated the capability of 
MALDI-MSI to unravel novel regions not previously reported by histology. 
 
Apart from trypsin, other enzymes can be applied directly on tissue. For instance, 
tissue sections can be treated with N-glycosidase F (PNGase F), which releases N-
linked glycans, or N-glycans, from glycoproteins. 95 The analysis of N-glycans is 
especially relevant in OA since these analytes are associated with the progression of 
the disease. 96 In fact, MALDI-MSI has been recently applied to spatially characterize 
the N-glycome in cartilage and subchondral bone of knee OA patients. 54 In this 
work, approximately 40 N-glycan structures were identified from cartilage and 
subchondral bone proteins by MALDI-MSI. Among them, high mannose N-glycans 
showed differential spatial distribution through the OA tissues. Particularly, 
(Man)3 + (Man)3 (GlcNAc)2 was found increased in cartilage compared to 
subchondral bone. In addition, OA patients with different bone marrow lesion stages 
were discriminated according to the (NeuAc)2 (Hex)2 (HexNAc)2+ 
(Man)3 (GlcNAc)2 profiles. The use of PNGase F and trypsin in combination with MSI 
can also increase the number of protein identifications while maintaining the spatial 
information. As an example, MALDI-MSI analysis of both N-linked glycans and 
proteolytic peptides from the same tissue section has been recently described. In this 
work, cancer tissue sections are sequentially digested using a combination of PNGase 
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Figure 2.2. Ex-vivo spatially-resolved proteomics applied to OA research. (A) Mass spectrometry 
imaging (MSI) workflow. (B) Liquid Extraction Surface Analysis (LESA) workflow. (C) Histology-
guided Laser Micro-Dissection (LMD) workflow: High spatial molecular information (≤10 μm) can be 
reached by MSI but with limited protein sensitivity. LESA or LMD technologies can achieve a better 
sensitivity but low spatial information. (D) MSI-guided proteomics workflow: In order to take 
advantage of the spatial molecular information as well as the sensitivity, MSI approach can be 
combined with LMD. 
 
2.4. Liquid extraction surface analysis 
 
Liquid Extraction Surface Analysis (LESA) involves the deposition of a droplet of 
solvent from a pipette tip to the surface. The solvent contacts the surface forming a 
liquid microjunction between the surface and the pipette tip allowing the analyte 
extraction from the tissue. Finally, the sample is re-aspirated, introduced into the 
mass spectrometer and ionized via ESI (Figure 2.2B) or transferred for LC-MS 
analysis. The technique can be coupled to bottom-up proteomics when introducing a 
proteolytic digestion step. 99, 100 As an example, Quanico et al. used a MALDI MSI-
guided approach to identify regions of anatomical interest. Using adjacent sections, 
these tissue regions were analyzed by LESA coupled to LC-MS/MS to improve 
sensitivity for protein identification. 100 
 
The combination of MALDI-MSI and LC-based proteomics is an alternative to 
enhance the protein identification rates. In this approach, a tissue section is analyzed 
by MSI while a consecutive section is homogenized and analyzed by LC-MS/MS. 
LC-MS/MS identification of peptides from parallel tissue sections allows the 
generation of specific peptide databases that benefit the identification of proteins in 
an imaging experiment. Therefore, different on-tissue protocols combined with 
bottom-up proteomics could be extremely useful to improve the detection and 
location of ECM proteins. However, a drawback of using consecutive sections here is 
that a full tissue extract is analyzed losing the specific signature of each region of 
interest (ROI) defined by MSI. 
 
2.5. Histology-guided laser capture micro-dissection 
 
Laser capture micro-dissection (LMD) was initially used to isolate cells or ROIs from 
tissues after staining (Figure 2.2C). 101 Among other methodologies, the samples can 
be then analyzed by LC-based proteomics. 102-104 A recent study conducted by 
Ezzoukhry, Z et al. demonstrated the possibility to perform fluorescence guided 
LMD using a modified cell line emitting red fluorescence. 105 In this case, the same 
tissue section can be used to correlate both histology and proteomics. LMD 
technology has been used to collect cartilage matrix from the territorial and 
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interterritorial regions at different depths (superficial, middle and deep) of cartilage 
derived from healthy and OA knees and hips. The proteomics results demonstrated 
that the degradation of the interterritorial regions is one of the main consequences of 
the disease, providing therefore direct evidence for dynamic remodeling of cartilage. 
106 
 
2.6. MSI-guided proteomics 
 
Recently, a new approach has been developed combining both MSI analysis and 
protein identification on the same tissue section (Figure 2.2D). In this strategy, 
specific ROIs identified by MALDI-MSI can be excised from the same tissue using 
LMD and then subjected to LC-MS/MS.107, 108 Alberts et al. have used this 
combination of MALDI-MSI with LMD-based microproteomics to investigate 
heterogeneity in breast tumors. 109 In this study, MALDI-MSI revealed differential 
protein signatures that discriminated heterogeneous regions within tumors. Each 
ROI was then isolated using LMD, subjected to trypsin digestion and analyzed by 
LC-MS/MS reporting >3000 proteins per region. This method could be applied to 
study cartilage heterogeneity, in order to gain more insight into regions with 
different proteomic profiles highlighted by MSI. 
 
2.7. Mass cytometry and multiplexed ion beam imaging as targeted 
spatially-resolved proteomics 
 
Imaging mass cytometry (IMC, or also called CyTOF) and multiplexed ion beam 
imaging (MIBI) are two new imaging methods that have been recently introduced in 
the biomedical field (Figure 2.3). 110 In IMC, different antibodies, selected to target 
specific proteins or protein modifications, are tagged with metal isotopes and used as 
reporters. Then, tissue samples are simultaneously stained with a maximum of 32 
metal-labeled antibodies, and the isotopes are visualized using MS. The two methods 
differ in how these tags are liberated from the sample, ionized and detected. In IMC, 
the UV laser ablates the tissue spot by spot, and the generated ions are transferred in 
a gas stream (usually a mixture of argon and helium) into the CyTOF mass 
spectrometer. The laser desorbed material is transferred to an inductively coupled 
plasma (ICP) ion source where the molecules are ionized. The metal isotope content 
and, therefore, protein expression and distributions, are then determined in the TOF 
mass analyzer. The method has been fully applied for cancer studies. 111, 112 On the 
other hand, in MIBI, secondary ion mass spectrometry is used to image metal 
isotopes. In this case, the tissue sample is incubated with different metal-labeled 
antibodies simultaneously. A primary (oxygen) ion beam is employed to raster the 
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sensitivity, resolution, complexity, and throughput. 114 For instance, there is no 
background signal due to autofluorescence, there are no matrix effects and neither 
secondary labeling nor amplification steps are required as is often used in 
immunohistochemistry. Additionally, both approaches have a wider dynamic range 
compared to immunofluorescence. IMC and MIBI can be combined with other 
complementary approaches such as MALDI-MSI data to have a more comprehensive 
view of different tissue components. 
One example of the utility of mass cytometry in OA research is illustrated by Paleja 
and collaborators in a study where CyTOF is employed in combination with next 
generation RNA-sequencing to immunophenotype the peripheral knee joint fluid 
and to identify pathways involved in the pathogenesis of the OA disease. 115 
Recently, the potential of CyTOF to enhance the discovery of cellular biomarkers for 
rheumatoid arthritis has also been illustrated. 116 
 
2.8. Conclusions and future perspectives 
 
Proteomic approaches are widely used and should be still considered to discover, 
quantify and characterize biomarkers due to their well-established capabilities. In the 
meantime, complementary technologies that retain the spatial information have 
rapidly evolved and already demonstrated their importance in the field. Spatially 
resolved proteomic approaches constitute a useful tool to reveal molecular key 
interactions and the interplay among different joint tissues. Particularly, MSI 
provides an ideal platform to reveal intra-tissue heterogeneity and precisely describe 
the spatial characteristics of pathophysiological protein changes in OA tissues 
including cartilage and synovium, as we outlined in this review. Moreover, MSI 
might constitute an alternative to measure protein PTMs, such as glycosylation, 
phosphorylation or other modifications affecting proteins such as histones. 117 As we 
stated above, an optimum combination of MSI techniques with further development 
of different methodologies is required to overcome the existing challenges for protein 
identification. Multimodal (imaging) approaches offer new opportunities to tackle 
these challenges and provide a better insight on the molecular mechanisms that lead 





This work has been performed as part of the M4I research program that was 
financially supported by the Dutch Province of Limburg through the “LINK” 
program and by the MUMC+ institutional grant for clinical collaborative research. 
  










































































































































3. Spatially resolved endogenous improved metabolite detection in 
human osteoarthritis cartilage by matrix assisted laser desorption 




Osteoarthritis (OA) is one of the most common musculoskeletal diseases, 
characterized by the progressive deterioration of articular cartilage. Although the 
disease has been well studied in the past few years, the endogenous metabolic 
composition and more importantly, the spatial information of these molecules in 
cartilage, is still poorly understood.  
 
Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging 
(MSI) has been previously used for the investigation of the bimolecular distribution 
of proteins and lipids through the in situ analysis of cartilage tissue sections. MALDI-
MSI as a tool to detect metabolites remains challenging, as these species are low 
abundant and degrade rapidly.  
 
In this work, we present a complete methodology, from sample preparation to data 
analysis for the detection of endogenous metabolites on cartilage by MSI. Our results 
demonstrate for the first time the ability to detect small molecules in fragile, 
challenging tissues through an optimized protocol, and render MSI as a tool towards 




Osteoarthritis (OA) is the most common form of arthritis and is mainly 
characterized by the progressive deterioration of articular cartilage. 118-120 The 
disease is also combined with structural changes to the entire joint, including 
the synovium121, the meniscus (for the knee)122, the periarticular ligaments 123 
and the subchondral bone.124 Many factors contribute to the complexity and 
heterogeneity of the disease. Genetic predisposition, trauma, mechanical 
loading and lifestyle have an impact on the various molecular pathways that 
define loadbearing and regenerative capacity of cartilage. It is this 
heterogeneity that needs the development of targeted personalized medicine 
for the treatment of OA.125 Classical approaches such as genomics, 
metabolomics or proteomics still remain essential to better understand the 
disease.126 However, these approaches require whole cartilage extracts and 
therefore they do not provide any spatial information of the biomolecules 
within the different layers of the tissue. One way to overcome this drawback is 
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to use matrix-assisted laser desorption/ionization (MALDI) mass spectrometry 
imaging (MSI) technology.  
 
MALDI-MSI allows for the investigation of the biomolecular distribution of 
proteins, lipids or metabolites through the analysis of a variety of tissue 
sections.46, 47 For cartilage, studies have been conducted on lipids52, 127 and 
peptides.53, 55, 92, 128 Nevertheless, the endogenous metabolic composition and 
more importantly the spatial information of these compounds have never been 
described. Amongst the matrices for metabolite detection, N-(1-naphthyl) 
ethylenediamine dihydrochloride (NEDC), 1,5-Diaminonapthalene (DAN) and 
9-Aminoacridine (9AA) are the most commonly used in the field of MSI.129, 130 
These matrices exhibit very few matrix-related interferences in the low-mass 
range, which remains advantageous for the simultaneous detection of a variety 
of cellular metabolites in negative ion mode such as adenosine 
tri/di/mono/phosphate compounds.131-133 MALDI-MSI applied to metabolites 
still remains challenging, especially due to the low abundance of these 
molecular species and their fast degradation. In addition, the low number of 
chondrocytes in the avascular, collagen rich extracellular matrix from cartilage 
tissue increases the difficulty to detect these compounds. As a consequence, an 
extensive sample preparation optimization i) to avoid tissue degradation as 
much as possible and ii) to increase extraction and detection of molecular 
signals by MALDI-MSI is required. Methods such as microwave irradiation134, 
135 and freeze-blowing136 have been used in studies to prevent enzymatic tissue 
degradation.137 One alternative to these methods is the stabilizor system, a 
device able to preserve proteins138 or the phosphorylation state 139 for tissue-
based proteomic studies with a heat stabilization process. More interestingly, 
approaches using this technology have been recently applied to preserve 
amino neurotransmitters140 or metabolites141 in MSI experiments on soft 
tissues. The application of this technology on cartilage can be combined with 
an optimized MALDI-MSI protocol in order to improve the detection of 
metabolites. However, protocol optimization remains time-consuming, 
especially in MALDI-MSI experiments, and can lead to ambiguous results if 
the important parameters are not well established. One way to efficiently 
optimize a protocol is to use a statistical design of experiment approach.142-144 
This approach reduces the number of experiments needed for protocol 
optimization and allows researchers to evaluate the influence of several 
parameters at once.  
 
In this study, we demonstrated the possibility to extract metabolites from 




especially meaningful to assess the disease state of cartilage. The first 
experiments enabled us to evaluate the capabilities of the stabilizor system to 
permanently prevent biological changes from the moment of sampling. Then, a 
statistical design of experiments software was used to optimize the matrix 
deposition parameters in the MALDI-MSI workflow, in order to increase the 
detection of metabolites while retaining their spatial distribution. Finally, 
optimized imaging experiments were executed, revealing metabolite 
information from cartilage tissue that could previously not be retrieved.  
 




The Maastricht University Medical Centre institutional policy on the use of 
residual human surgical material states that no informed consent is needed in 
the case of residual surgical material. Human OA cartilage was obtained from 
three OA patients undergoing total knee joint replacement. Unwounded 
cartilage explants of 8*8mm were either heat stabilized by a stabilizor system 
(Denator, Uppsala) before freezing or immediately snap frozen and stored at -
80°C. Snap-frozen tissues were sectioned at 12 µm thickness with a cryostat 
(Leica Microsystems, Wetzlar) at -20°C and thaw mounted on cleaned indium 




Ten µL of 9AA matrix (Sigma-Aldrich, Zwijndrecht, The Netherlands) was 
used (7 mg/mL in 70% Ethanol) for the extraction of metabolites from cartilage 
sections and analyzed in duplicate by MALDI-MS in negative ion mode. 
Norharmane matrix (Sigma-Aldrich) at 7 mg/mL in chloroform/methanol 
(2:1, (v/v)) was used for lipid analysis in negative ion mode. 
 
Metabolite analysis was performed using a MALDI-FT-ICR-MS instrument 
(SolariX, Bruker Daltonik GmbH, Bremen, Germany) at 300-600 m/z with 230 
laser shots at a laser repetition frequency of 2000 Hz and ion accumulation 
time of 5 milliseconds in the cell. Instrument external calibration was 
performed in negative ion mode using a standard calibration mixture of red 
phosphorous (Sigma-Aldrich). Instrument internal calibration was performed 
with reference masses of metabolites; adenosine monophosphate (AMP) at m/z 
346.0558, adenosine diphosphate (ADP) at m/z 426.0221 and adenosine 
triphosphate (ATP) at m/z 505.9884, using FTMS Processing V2.1 (Bruker 
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Daltonik GmbH) and Compass Isotope Pattern V3.0 (Bruker Daltonik GmbH) 
to reach a mass error below 1 ppm.  
 
Lipids were detected with norharmane matrix over the mass range m/z 400-
1400 Da using a Bruker RapifleX MALDI Tissue-typer instrument operating in 
reflectron mode.  
MS/MS experiments were performed using a SYNAPT G2Si instrument 
(Waters Corporation, Manchester, U.K.) to confirm the identification of 




The HTX TM-Sprayer (HTX Imaging, Chapel Hill) was used to spray 9AA 
matrix for sample preparation. A SYNAPT G2Si instrument was used to 
compare the different protocols and acquire the imaging data over the mass 
range m/z 100-1000 in negative ion mode using the sensitivity mode and a scan 
time of 1 second per pixel. The Nd:YAG MALDI laser was operated at a firing 
rate of 1000 Hz with a lateral resolution of 100 µm. A SolariX FT-ICR-MS 
instrument was used to validate the experimental model in imaging mode. FT-
ICR MSI data was acquired with a lateral resolution of 40 µm. Ion 
accumulation time in the cell was set up at 5 milliseconds and 400 laser shots at 




Compass DataAnalysis software V4.4 and FTMS Processing V2.1 were used to 
visualize the mass spectra and to calculate the signal to noise for each 
metabolite of interest in profiling mode. 
 
For the experimental design approach, acquired data were processed and 
analyzed using HDI Imaging software V1.4 (Waters Corporation) by extracting 
the 1000 most abundant ions with the following settings: m/z window = 0.02 
Da and MS resolution = 15000. Intensities were normalized by Total Ion Count 
(TIC) and Regions of Interest (ROIs) were manually created. Finally, intensities 
of ATP, ADP and UDP from these ROIs were used for elaborating the 
experimental design response variables as input into Aexd.net (Alleviating 
Science).145 
 
Aexd.net was used to generate an experimental design in a six steps approach: 
i) creation of the first experimental design table, ii) acquisition of the data 




iii) statistical analysis of the results with generation of a model and definition 
of significant parameters of the HTX TM-Sprayer, iv) creation of the second 
experimental design table, v) acquisition of the data through the second set  of 
experiments and data input into the software, vi) statistical analysis and 
visualization of the final results. The experimental design used a Plackett-
Burman (PB-12+3) design followed by a surface response analysis of a central 
composite rotatable design (CCRD 2^2+2x2+3). Importantly, the step vi 
allowed for the creation of regression models for each response variable to 
describe the influence of variation in the dependent variables on the response 
variables. The parameters of the HTX TM-Sprayer used in the experimental 
design were the following: temperature, flow rate, drying time, number of 
layers, matrix concentration and percentage of solvent used to dissolve the 
matrix.  
 
SCiLS lab 2019b software was used to calculate the metabolite intensities inside 
and outside the tissues (SCiLS lab, GmbH, Bremen, Germany) after root mean 
square (RMS) normalization for the imaging experiments acquired by FT-ICR-
MS. The SQLite files generated were converted at a bin size of m/z 0.001 to 
MATLAB 2016b (The MathWorks, MA, USA) and in-house developed PEAPI 
software146 was then used for peak-picking.  
Finally, principal component analysis (PCA) followed by cluster analysis were 
applied to study the spatial metabolic distribution using an in-house 
ChemomeTricks toolbox for MATLAB. The Human Metabolome Database 
(HMDB) V4.0 and Metlin software V3.7.1 were used for molecular assignments 
with a tolerance up to 1 ppm. Drugs and exogenous compounds were 




Safranin O staining procedure was used to discern the superficial area from the 
deep area of the cartilage. For this, matrix was removed by immersion in 70% 
ethanol and the sections were then stained using hematoxylin (Sigma-Aldrich) 
for 8 min, Safranin O (Sigma-Aldrich) 0.1% dissolved in ultrapure H2O for 2 
min and Fast Green FCF (Sigma-Aldrich) 0.1% dissolved in ultrapure H2O for 
4 min. Finally, digital images were acquired with the Mirax desk slide scanner 
V2.6 software (Carl Zeiss, Gottingen, Germany) after dehydrating steps. 
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accurate mass (MS1). HMDB and METLIN software were used for molecular assignments with a 
tolerance up to 1 ppm. Drugs and exogenous compounds were excluded during the search. 
 
 
Complementary data showed the possibility to detect enhanced intensities of 
lipid species. As an example, the m/z at 885.5 was 3-fold enhanced when using 
norharmane on heat stabilized cartilage samples (Figure 3.2). 885.5 m/z was 
identified as phosphatidylinositol [PI 18:0_20:4-H]-, a well-known lipid 
detectable from a large variety of tissues in MSI experiments.149-151 These data 
indicate that the use of the stabilizor system boosts the detection of other 
biomolecular classes.  
 
Theoretical Experimental Chemical
m/z  value m/z  value Formula
CMP* [M-H]¯ 322.0446 322.0448 0.70 C9H14N3O8P -
UMP* [M-H]¯ 323.0286 323.0288 0.65 C9H13N2O9P -





GMP* [M-H]¯ 362.0507 362.0507 0.06 C10H14N5O8P -
UDP* [M-H2O-H]¯ 384.9844 384.9848 1.15 C9H14N2O12P2 -
78.95
158.91
ADP* [M-H2O-H]¯ 408.0116 408.0118 0.55 C10H15N5O10P2 -







GDP* [M-H]¯ 442.0171 442.0170 0.12 C10H15N5O11P2 -
ADP* [M+Na-2H]¯ 448.0041 448.0048 1.60 C10H15N5O10P2 -





GTP* [M-H]¯ 521.9834 521.9840 1.15 C10H16N5O14P3 -
ATP* [M+Na-2H]¯ 527.9704 527.9708 0.73 C10H16N5O13P3 -
158.91
408.01
Sodium ATP* [M+Na-2H]¯ 549.9524 549.9528 0.80 C10H15N5NaO13P3 -
UDP-Glucose/Galactose* [M-H]¯ 565.0477 565.0484 1.20 C15H24N2O17P2 -
UDP-N-Acetyl 
Glucosamine/Galactosamine*
ADP-Ribose [M-H2O-H]¯ 540.0538 540.0538 0.06 C15H23N5O14P2
[M-H]¯ 606.0743 606.0754 1.80 C17H27N3O17P2 -
C10H16N5O13P3
ADP [M-H]¯ 426.0221 426.0228 1.50 C10H15N5O10P2
ATP [M-H]¯ 505.9885 505.9888 0.65
C9H14N2O12P2
Assignment Designation PPM error MS/MS fragments
AMP [M-H]¯ 346.0558 346.0558 C10H14N5O7P
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the data showed that ethanol percentage and drying time might be critical to 
keep the spatial intra-tissue metabolic distribution, meaning to differentiate 
superficial and deep areas of the cartilage. Another experimental design model 
should be considered to statistically validate this hypothesis. Based on our 
results, methods 1 and 2 are equally optimal to study the metabolic spatial 
distribution in cartilage.  
 
3.5. Chapter conclusions 
 
To the best of our knowledge, this is the first study that reports the detection of 
endogenous metabolites in cartilage using MALDI-MSI. We showed the 
efficiency of heat stabilization to preserve endogenous metabolites within the 
cartilage and demonstrated for the first time the potential of experimental 
design to optimize MALDI-MSI sample preparation protocols. Especially, the 
optimized results revealed a higher presence of metabolites in the superficial 
area of the cartilage. This method could be employed to further study 





The work was performed as part of the M4I research program that was 
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CHAPTER  4 
Heterogeneity in lipid and protein cartilage 
profiles associated with human osteoarthritis 
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4. Heterogeneity in lipid and protein cartilage profiles associated with 




Osteoarthritis (OA) is a multifactorial pathology and comprises a wide range of 
distinct phenotypes. In this context, the characterization of the different molecular 
profiles associated with each phenotype can improve the classification of OA for 
better therapies. In particular, OA can co-exist with type 2 diabetes mellitus (T2DM). 
This study investigates lipidomic and proteomic differences between human 
OA/T2DM- and OA/T2DM+ cartilage through a multimodal mass spectrometry 
approach. 
 
Human cartilage samples were obtained after total knee replacement from 
OA/T2DM- (n=10) and OA/T2DM+ patients (n=10). Label-free proteomics was 
employed to study differences in protein abundance and matrix-assisted laser 
desorption/ionization (MALDI) mass spectrometry imaging (MSI) for spatially 
resolved-lipid analysis. 
 
Label-free proteomic analysis showed differences between OA/T2DM- and 
OA/T2DM+ phenotypes in several metabolic pathways such as lipid regulation. 
Interestingly, the phospholipase A2 protein (PLA2G2A), was found overexpressed 
within the OA/T2DM+ cohort. In addition, MALDI-MSI experiments revealed that 
phosphatidylcholine (PC) and sphingomyelin (SM) species were characteristic of the 
OA/T2DM- whereas lysolipids were more characteristic of the OA/T2DM+ 
phenotype. The data also pointed out differences in phospholipid content between 
superficial and deep layers of the cartilage.  
 
Our study shows distinctively different lipid and protein profiles between 
OA/T2DM- and OA/T2DM+ human cartilage, demonstrating the importance of sub-




Osteoarthritis (OA) is mainly characterized by the progressive deterioration of 
articular cartilage and it is the most common form of arthritis worldwide, affecting 
over 10% of the population above 60 years.4, 118, 154 OA is recognized as an age-related 
joint disease3, 155 but an increasing number of risk factors have been associated with 
the development of the pathology.5 Therefore, OA is considered as a multifactorial 
pathology which suggests a wide range of distinct phenotypes rather than a single 
Heterogeneity in lipid and protein cartilage profiles associated with human osteoarthritis with or 
without type 2 diabetes mellitus 
52 
disease.156 However, all the patients receive similar treatments regardless of these 
phenotypes.157  
Models for patient classification have been proposed to try to establish different OA 
phenotypes.7, 158 The classification of OA patients into different groups can 
significantly transform OA clinical trials and enhance their efficiency towards a 
personalized medicine approach. From the phenotypes proposed in the literature, 
the metabolic syndrome phenotype is defined by chronic low-grade inflammation, 
which leads to systemic and local molecular changes.8  The metabolic syndrome is 
defined as a health disorder that increases the risk of type 2 diabetes mellitus 
(T2DM), hypertension, or dyslipidemia.13 Interestingly, different studies have shown 
a correlation between T2DM and OA15, 16 and a higher prevalence of OA in T2DM 
patients.17, 159 To better understand this predisposition, the basic molecular (i.e. 
proteins and lipids) mechanisms underlying the pathological processes of both 
diseases need to be considered. 
In this work, we hypothesized that OA/T2DM- and OA/T2DM+ human knee 
cartilage present differential molecular profiles. For this purpose, label-free 
proteomics and spatially resolved lipidomics using a matrix-assisted laser 
desorption/ionization (MALDI) mass spectrometry imaging (MSI), have been 
employed.  
 




The Maastricht University Medical Centre’s institutional policy on the use of residual 
human surgical material states that no informed consent is needed in the case of 
residual surgical material (METC number of the WMO approval waste material 
TKA: 2017-0183). Human cartilage from OA/T2DM- (n=10) and OA/T2DM+ patients 
(n=10) was obtained from donors undergoing total knee joint replacement. 
Additional information such as age, gender, affected knee, body mass index (BMI), 
and Kellgren-lawrence (KL) scores can be found in table 4.1. 
 
Table 4.1. Patient information. The (*) displayed the samples used for the comparative MALDI-MSI 









Unwounded cartilage areas were selected macroscopically, cut into punches of 8 mm 
and heat stabilized (Denator, Uppsala, Sweden) to avoid molecular degradation 
before being snap-frozen in liquid nitrogen and stored at -80°C. 160-162 The punches 
were finally sectioned at 12 µm thickness with a cryostat (Leica Microsystems, 
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(Sigma-Aldrich, Zwijndrecht, the Netherlands) containing 5 M Urea (GE Healthcare, 
Eindhoven, the Netherlands) and 0.2% Rapigest (Waters Corporation, MA, USA) 
were added to the 20 samples. Proteins were then extracted by freeze-thaw cycles 
(3X), with 1 minute of sonication step between each cycle. After 30 minutes of 
centrifugation at 14.000 rpm at 4°C, the supernatant containing proteins was finally 
transferred into new tubes and stored at -80° until further analysis. Bradford assay 
(Biorad, Lunteren, The Netherlands) was performed to assess the protein 
concentration. 
 
Label-free proteomics – Gel electrophoresis 
 
10 µg of proteins of each patient were loaded on a 12% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and run shortly for 4 minutes at 180 
volts. The gel was stained with Coomassie blue (Sigma-Aldrich) for protein 
visualization. The protein bands were excised from the gel and processed on a 
MassPREP digestion robot (Waters, Manchester, UK). The destaining of the 
Coomassie was performed using 50 mM of ABC buffer mixed with 50% acetonitrile 
(Biosolve, Valkenswaard, the Netherlands). Then, cysteines were reduced with 10 
mM dithiothreitol (Sigma-Aldrich) in 100 mM ABC for 30 minutes followed by 
alkylation with 55 mM iodoacetamide (Sigma-Aldrich) in 100 mM ABC for 20 
minutes in the dark. Spots were washed with 100 mM ABC to remove excess 
reagents and dehydrated with 100% acetonitrile. Trypsin (Promega, Leiden, the 
Netherlands) at 6 ng/ul in 50 mM ABC was added to the gel plugs and incubated at 
37°C for 5 hours. The peptides were finally extracted three times with 50 µl of 1% 
formic acid (Biosolve) and 2% acetonitrile. The volume of the peptide extract was 
reduced in a speedvac until a final volume of 50 µl was reached. 
 
Label-free proteomics – Data acquisition and processing 
 
400 ng of protein were injected for liquid-chromatography mass spectrometry (LC-
MSMS) analysis. The separation of the peptides was performed on a Thermo Fisher 
Scientific Dionex Ultimate 3000 Rapid Separation ultrahigh-performance liquid-
chromatography (HPLC) system (Thermo Scientific, MA, USA) equipped with an 
Acclaim PepMap C18 analytical column (2µm, 75µm*500 mm, 100Å). The samples 
were first trapped on an online C18 column for desalting. The peptides were then 
separated on the analytical column with a 180-minutes linear gradient from 5% to 
45% acetonitrile/0.1% formic acid and a flow rate set at 300 nL/min. The HPLC 
system was coupled on-line to a high-mass resolution orbitrap MS Q-Exactive 
instrument (Thermo Scientific) with a nano-electrospray Flex ion source (Proxeon, 
Thermo Scientific, MA, USA). The mass spectrometer was operated in positive ion 
polarity in data-dependent acquisition (DDA) mode with the following settings: Full 
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MS scan of the mass range m/z 250-1,250 at a resolution of 70,000 at m/z 200 with a 
maximum injection time of 120 ms, followed by tandem mass spectrometry (MS/MS) 
scans for the fragmentation of the 10 most intense ions at a resolution of 17,500. 
Isolation of precursors was performed with a 1.8 m/z window and a maximum 
injection time of 200 ms. The ions already selected for fragmentation were 
dynamically excluded for 30s. External calibration of the instrument was performed 
using a standard calibration solution for positive ion mode (Thermo Scientific).  
For protein identification, raw files were processed within the Proteome Discoverer 
software version 2.2 (Thermo Scientific) using the search engine Sequest with the 
Swiss-Prot human database Homo sapiens version 2020-02-10 (TaxID 9606). The 
following parameters were used for the database search: Carbamidomethylation of C 
for fixed modifications; oxidation of M and acetylation of protein N-term for variable 
modifications; trypsin for enzyme with a maximum of two missed cleavages; the 
precursor mass tolerance was set at 10 ppm and the fragment tolerance at 0.02 Da; 
minimum and maximum peptide length of 6 and 144 amino acids, respectively. 
Normalization of the data was performed on the total peptide amount. Percolator 
was used for the decoy database search and the FDR was fixed at 1% maximum. For 
protein quantitation, the Minora Feature Detector node in the processing step and the 
Feature Mapper node combined with the Precursor Ions Quantifier node in the 
consensus step were used with default settings. 
 
Label-free proteomics – Data analysis 
 
ANOVA test was performed within the Proteome Discoverer software to analyze the 
statistical significance of variation observed in protein abundance between the 
OA/T2DM- and OA/T2DM+ patients. The proteins were considered modulated with 
an adjusted p-value≤0.05 and a fold change (FC) cut-off set at 1.5-fold. The 
modulated proteins were then imported within the EnrichR software 163 to display 
the top 10 pathways of down or up-regulated proteins ranked by the combined score. 
WikiPathways and KEGG were used as databases (version 2019, Human).  
 
MALDI-MSI – Matrix application 
 
12 µm tissue sections were thaw mounted over cleaned indium tin oxide (ITO) glass 
slides (Delta Technologies, CO, USA) coated with double-sided conductive copper 
tape 1182 (3M Science, MN, USA). Norharmane (Sigma-Aldrich) was used as a 
matrix for lipid analysis. Eight layers of the matrix at 7 mg/mL in 
chloroform/methanol (2:1, (v/v)) were sprayed at 30°C with a flow rate of 0.12 
mL/min using the HTX TM-Sprayer system (HTX Imaging, NC, USA). A drying 
time of 30s between each layer and a velocity set at 1200 mm/min were used to 




MALDI-MSI – Data acquisition and processing 
 
MALDI-MSI experiments were performed in positive ion polarity at 50 µm of lateral 
resolution using a RapifleX MALDI Tissue-typer instrument operating in reflectron 
mode (Bruker, Bremen, Germany) to compare the lipidomic profiles of OA/T2DM- 
and OA/T2DM+ patients. Lipids were detected over the mass range m/z 300-1600.  
 
A Waters Synapt G2Si coupled to a µMALDI source (Waters) with a lateral resolution 
of 15 µm in combination with the Waters Research Enabled Software (WREnS) was 
employed for high spatial resolution MALDI-MSI experiments. 164 The following 
settings were used for the data acquisition: mass range m/z 400-1200, automatic 
quadrupole mode profile and laser pulse energy of 300 (a.u). External calibration on 
both instruments was performed using the standard calibration mixture of red 
phosphorous (Sigma-Aldrich) with a mass error below 10 ppm. 
 
For the DDA-imaging experiments, a MALDI-MSI method that enables data-
dependent acquisition (DDA) of tandem mass spectrometry data in parallel with a 
high-mass resolution mass spectrometry imaging experiment was employed. 165 The 
experiments were carried out on OA/T2DM- and OA/T2DM+ tissue sections with a 
stage step size of 25 µm (horizontal) × 50 µm (vertical) and performed in positive ion 
polarity using the orbitrap Elite hybrid ion trap mass spectrometer over the mass 
range m/z 200-2000. A resolution of 240,000 at m/z 400 with a maximum injection time 
of 250 ms for the orbitrap was used. The MSMS were performed in the ion trap using 
the following settings: isolation of precursors set at 0.7 m/z window and activation q: 
0.17. The CID was used using a normalized collision energy (NCE) set up at 30 eV. 
External calibration of the instrument was performed as described in the label-free 
proteomics section. 
 
MALDI-MSI – Data analysis 
 
For the MALDI-MSI comparative approach, raw data were processed by SCiLS lab 
software version 2019b (SCiLS, Bremen, Germany). Principal component analysis 
(PCA) and linear discriminant analysis (LDA) were performed after peak picking 
using an in-house-built ChemomeTricks toolbox for MATLAB version 2012B (The 
MathWorks, MA, USA). 146  
 
For the µMALDI experiment, data were processed using the High Definition Imaging 
software version 1.4 (Waters) by extracting the 1000 most abundant ions with the 
following settings: m/z window set at 0.02 Da and MS resolution at 15000. Processed 
data were then exported to imzML format before being imported into SCiLS lab 
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MultiVendor Support (MVS) software version 2019b. Within the software, the 
standard segmentation pipeline using bisecting k-means algorithm and a pLSA 
analysis with random initialization were performed on the data normalized by total 
ion current (TIC) with weak denoising and with an m/z interval width set to ± 0.1 Da. 
 
For the DDA-imaging approach, lipid assignments were performed within 
lipostarMSI software version 1.0 and manually checked using Xcalibur software 
version 4.2. 166 Within the lipostarMSI software, the following settings were used: the 
precursor and the fragments mass tolerances were set at 3 ppm and 0.25 ppm, 
respectively, and the lipid assignments were based in at least 10 or more MS/MS 
scans. 
 
MALDI – Lipid identification 
 
Lipids of interest were identified using targeted MS/MS analysis performed in the 
ion trap of the orbitrap Elite hybrid ion trap mass spectrometer (Thermo Scientific). 
The collision induced dissociation (CID) was used to fragment the precursors within 
an isolation window of 1 Da and with a normalized collision energy (NCE) set up at 
30 eV. Each precursor from the inclusion list was measured for 1 minute in a 
continuous acquisition mode. For low abundant species, lipid extraction was 
performed in chloroform/methanol (2:1, (v/v)) with 50 µmol of  ammonium formate 
(Biosolve). The extract was then analysed using the high-mass resolution orbitrap MS 
Q-Exactive instrument using electrospray ionization (ESI). External calibration of the 
instrument was performed as described in the label-free proteomics section. Lipids 
were assigned manually using Xcalibur software version 4.2 and tentatively assigned 




Matrix was removed by immersion in 70% ethanol. The sections were then stained 
using hematoxylin (Sigma-Aldrich) for 8 minutes, Safranin O (Sigma-Aldrich) 0.1% 
dissolved in ultrapure H2O for 2 minutes and Fast Green FCF (Sigma-Aldrich) 0.1% 
dissolved in ultrapure H2O for 4 minutes. Finally, digital images were acquired with 
the M8 scanner (Precipoint, Freising, Germany) after dehydrating steps. 
 
4.4. Results and discussion 
 




Label-free proteomics followed by enrichment analysis of the differentially expressed 
proteins, is a powerful tool to investigate specific pathways associated with OA 
subgroups. After data processing, a total of 1605 proteins were identified. Among 
them, 115 displayed statistically significant differences (adjusted p-value≤0.05; FC 
cut-off set at 1.5-fold) between the two conditions (Table 4.2).  
 
Table 4.2. Significantly up and down-regulated proteins found in OA/T2DM- compared to 
OA/T2DM+. The FC cut-off is at 1.5-fold and adjusted p-value is ≤ 0,05. 75 proteins were found 





Protein ID Protein Name Fold change p-value
O75828 Carbonyl reductase [NADPH] 3 0.01 1.99E-16
P13796 Plastin-2 0.01 1.99E-16
P02778 C-X-C motif chemokine 10 0.01 1.99E-16
P43121 Cell surface glycoprotein MUC18 0.01 1.99E-16
P15144 Aminopeptidase N 0.01 1.99E-16
P02730 Band 3 anion transport protein 0.01 1.99E-16
P36269 Glutathione hydrolase 5 proenzyme 0.01 1.99E-16
Q99439 Calponin-2 0.01 1.99E-16
Q6UWY5 Olfactomedin-like protein 1 0.01 1.99E-16
P13591 Neural cell adhesion molecule 1 0.01 1.99E-16
P35222 Catenin beta-1 0.01 1.99E-16
P35542 Serum amyloid A-4 protein 0.01 1.99E-16
P13686 Tartrate-resistant acid phosphatase type 5 0.01 1.99E-16
P27918 Properdin 0.01 1.99E-16
Q08397 Lysyl oxidase homolog 1 0.01 1.99E-16
P55290 Cadherin-13 0.01 1.99E-16
Q08188 Protein-glutamine gamma-glutamyltransferase E 0.01 1.99E-16
Q9Y333 U6 snRNA-associated Sm-like protein LSm2 0.01 1.99E-16
Q9NZ08 Endoplasmic reticulum aminopeptidase 1 0.01 1.99E-16
Q13451 Peptidyl-prolyl cis-trans isomerase FKBP5 0.01 1.99E-16
P47985 Cytochrome b-c1 complex subunit Rieske, mitochondrial 0.01 1.99E-16
P49821 NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial 0.01 1.99E-16
P10451 Osteopontin 0.08 1.99E-16
Q9BRX8 Peroxiredoxin-like 2A 0.11 1.99E-16
O60938 Keratocan 0.24 2.71E-05
P10620 Microsomal glutathione S-transferase 1 0.24 3.72E-08
P00915 Carbonic anhydrase 1 0.24 7.42E-13
P68400 Casein kinase II subunit alpha 0.28 4.49E-06
Q16647 Prostacyclin synthase 0.29 1.13E-03
P27487 Dipeptidyl peptidase 4 0.30 2.93E-03
P02452 Collagen alpha-1(I) chain 0.30 4.33E-09
Q4ZHG4 Fibronectin type III domain-containing protein 1 0.31 1.79E-03
P02647 Apolipoprotein A-I 0.31 1.35E-08
P62834 Ras-related protein Rap-1A 0.31 1.41E-06
P61086 Ubiquitin-conjugating enzyme E2 K 0.32 6.00E-04
Q7Z304 MAM domain-containing protein 2 0.32 2.17E-03
P16219 Short-chain specific acyl-CoA dehydrogenase, mitochondrial 0.32 4.33E-03
P02652 Apolipoprotein A-II 0.34 4.50E-03
Q9BX68 Histidine triad nucleotide-binding protein 2, mitochondrial 0.35 2.21E-02
P08572 Collagen alpha-2(IV) chain 0.35 6.38E-03
Q9UI09 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 0.36 3.06E-02
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P56385 ATP synthase subunit e, mitochondrial 0.36 9.09E-03
P78539 Sushi repeat-containing protein SRPX 0.37 8.86E-03
P49327 Fatty acid synthase 0.40 4.01E-02
P23141 Liver carboxylesterase 1 0.41 4.77E-02
Q13103 Secreted phosphoprotein 24 0.42 1.74E-02
P36955 Pigment epithelium-derived factor 0.43 2.53E-04
P24592 Insulin-like growth factor-binding protein 6 0.44 4.16E-02
P02750 Leucine-rich alpha-2-glycoprotein 0.44 8.81E-03
P21589 5'-nucleotidase 0.44 5.68E-04
P55854 Small ubiquitin-related modifier 3 0.44 2.46E-03
P09486 SPARC 0.45 1.13E-04
P04179 Superoxide dismutase [Mn], mitochondrial 0.47 2.32E-03
Q96CX2 BTB/POZ domain-containing protein KCTD12 0.47 3.10E-02
P08123 Collagen alpha-2(I) chain 0.48 3.19E-03
Q07507 Dermatopontin 0.49 5.12E-03
P05452 Tetranectin 0.49 5.41E-03
Q6UXI7 Vitrin 0.49 5.51E-03
P21980 Protein-glutamine gamma-glutamyltransferase 2 0.49 5.72E-03
P62750 60S ribosomal protein L23a 0.49 3.39E-02
P62424 60S ribosomal protein L7a 0.50 7.94E-03
P36542 ATP synthase subunit gamma, mitochondrial 0.50 1.53E-02
Q96CG8 Collagen triple helix repeat-containing protein 1 0.50 9.20E-03
P08294 Extracellular superoxide dismutase [Cu-Zn] 0.51 1.08E-02
Q9UBI6 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-12 0.51 1.73E-02
Q8IUE6 Histone H2A type 2-B 0.51 3.67E-02
Q5T749 Keratinocyte proline-rich protein 0.52 5.82E-03
P40429 60S ribosomal protein L13a 0.53 3.33E-02
Q53TN4 Cytochrome b reductase 1 0.54 3.47E-02
P52566 Rho GDP-dissociation inhibitor 2 0.54 3.99E-02
Q99715 Collagen alpha-1(XII) chain 0.54 3.39E-02
Q9BXN1 Asporin 0.54 3.75E-02
O60814 Histone H2B type 1-K 0.54 4.01E-02
P02790 Hemopexin 0.55 2.46E-02
P29279 CCN family member 2 0.57 4.41E-02
O75339 Cartilage intermediate layer protein 1 1.51 8.64E-03
P83110 Serine protease HTRA3 1.52 6.97E-03
P34096 Ribonuclease 4 1.55 4.77E-03
P03950 Angiogenin 1.57 4.09E-03
P06727 Apolipoprotein A-IV 1.59 2.83E-03
Q9NRA1 Platelet-derived growth factor C 1.63 2.50E-03
Q92743 Serine protease HTRA1 1.63 1.64E-03
P61626 Lysozyme C 1.71 5.68E-04
P35625 Metalloproteinase inhibitor 3 1.73 4.28E-04
Q02818 Nucleobindin-1 1.78 2.17E-02
P02489 Alpha-crystallin A chain 1.79 1.80E-04
O15232 Matrilin-3 1.81 1.34E-04
Q9UHY7 Enolase-phosphatase E1 1.83 8.52E-03
P14555 Phospholipase A2, membrane associated 1.90 3.30E-05
Q687X5 Metalloreductase STEAP4 1.94 5.97E-06
P63220 40S ribosomal protein S21 1.94 2.20E-05
P00352 Retinal dehydrogenase 1 2.42 9.10E-07
P02766 Transthyretin 2.95 4.90E-12
A8K7I4 Calcium-activated chloride channel regulator 1 3.00 6.17E-09
Q7L211 Protein ABHD13 3.85 1.99E-16





Among those, 75 were more abundant in OA/T2DM- samples whereas 40 were more 
abundant in OA/T2DM+ patients. Enrichment analysis performed on these proteins 
revealed specific pathways of interest (Table 4.3).  
 
Table 4.3. Top 10 enriched pathways from WikiPathways and KEGG databases. The highlighted 
pathways in blue are related to lipid-related pathways. 
P07315 Gamma-crystallin C 5.05 1.99E-16
P11844 Gamma-crystallin A 5.43 1.99E-16
P05813 Beta-crystallin A3 6.35 1.99E-16
Q06141 Regenerating islet-derived protein 3-alpha 10.72 1.99E-16
P17661 Desmin 100.00 1.99E-16
Q03013 Glutathione S-transferase Mu 4 100.00 1.99E-16
Q01524 Defensin-6 100.00 1.99E-16
P07148 Fatty acid-binding protein, liver 100.00 1.99E-16
P17096 High mobility group protein HMG-I/HMG-Y 100.00 1.99E-16
P53672 Beta-crystallin A2 100.00 1.99E-16
P50440 Glycine amidinotransferase, mitochondrial 100.00 1.99E-16
Q14956 Transmembrane glycoprotein NMB 100.00 1.99E-16
Q14258 E3 ubiquitin/ISG15 ligase TRIM25 100.00 1.99E-16
Q14117 Dihydropyrimidinase 100.00 1.99E-16
P08246 Neutrophil elastase 100.00 1.99E-16
P53674 Beta-crystallin B1 100.00 1.99E-16
O00175 C-C motif chemokine 24 100.00 1.99E-16
P08473 Neprilysin 100.00 1.99E-16
Q8TF66 Leucine-rich repeat-containing protein 15 100.00 1.99E-16
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Interestingly, a high number of lipid-related pathways were found in both 
OA/T2DM- (composition of lipid particles; vitamin B12 metabolism; metabolic 
pathway of LDL, HDL, and TG, including diseases; folate metabolism) and 
OA/T2DM+ phenotypes (fatty acid omega oxidation; glycerophospholipid 
biosynthetic pathway; PPAR alpha pathway; eicosanoid synthesis). In particular, 
composition of lipid particles, vitamin B12 metabolism, and metabolic pathway of 
LDL, HDL and TG were considered significantly characteristic of the OA/T2DM- 
group.  
Using the KEGG database, we also identified three lipid metabolic pathways 
upregulated in the OA/T2DM- group (riboflavin metabolism; arachidonic acid 
metabolism; fatty acid biosynthesis). In addition, fat digestion and absorption, 
Pathway ID Pathway description P-value (p) Combined score
WP3601 composition of lipid particles 4.91E-04 451.49
WP1533 vitamin B12 metabolism 3.69E-05 217.78
WP4522 metabolic pathway of LDL, HDL and TG, including diseases 1.61E-03 214.40
WP12 osteoclast signaling 1.61E-03 214.40
WP408 oxidative stress 2.55E-04 200.60
WP3967 miR-509-3p alteration of YAP1/ECM axis 1.82E-03 197.94
WP176 folate metabolism 1.10E-04 147.28
WP2911 miRNA targets in ECM and membrane receptors 3.05E-03 140.40
WP100 glutathione metabolism 3.34E-03 132.24
WP111 electron transport chain (OXPHOS system in mitochondria) 4.26E-05 130.27











Pathway ID Pathway description P-value (p) Combined score
WP1589 folate-alcohol and cancer pathway hypotheses 1.79E-02 223.62
WP4225 pyrimidine metabolism and related diseases 1.79E-02 223.62
WP4146 macrophage markers 1.79E-02 223.62
WP206 fatty acid omega oxidation 2.96E-02 117.34
WP497 urea cycle and metabolism of amino groups 3.93E-02 80.93
WP2533 glycerophospholipid biosynthetic pathway 4.12E-02 75.94
WP3580 methionine de novo and salvage pathway 4.31E-02 71.45
WP1539 angiogenesis 4.69E-02 63.73
WP2878 PPAR alpha pathway 5.08E-02 57.32
WP167 eicosanoid synthesis 5.27E-02 54.52























KEGG database (Human) – OA/T2DM- group
Name Adjusted p-value (q)





arachidonic acid metabolism 6.59E-02





fatty acid biosynthesis 4.90E-01










KEGG database (Human) – OA/T2DM+ group
Name Adjusted p-value (q)
fat digestion and absorption 2.31E-02
pantothenate and CoA biosynthesis 1
renin-angiotensin system 1
vitamin digestion and absorption 1
alpha-linolenic acid metabolism 1




glycine, serine and threonine metabolism 1
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pantothenate and CoA biosynthesis, vitamin digestion and absorption, alpha-
linolenic acid metabolism and linoleic acid metabolism were upregulated in the 
OA/T2DM+ group.  
From all the differently regulated proteins, the apolipoprotein A-1 (APOA1) has been 
found in 4/7 of the lipid metabolic pathways in the OA/T2DM- group (composition 
of lipid particles; vitamin B12 metabolism; metabolic pathway of LDL, HDL and TG, 
including diseases; folate metabolism). APOA1 protein is the major constituent of 
HDL, and therefore plays a key role in the lipoprotein metabolism. 168 De Seny et al. 
demonstrated the potential pro-inflammatory properties of the protein in the context 
of OA disease. 169 A higher level of APOA1 was observed in the serum of healthy 
control individuals compared to OA patients. 170 Moreover, T2DM has been recently 
correlated with low levels of APOA1 also in the serum. 171  
In the OA/T2DM+ cohort, the phospholipase A2 protein, membrane associated 
(PLA2G2A) has been found linked to 5/9 lipid metabolic pathways 
(glycerophospholipid biosynthetic pathway; eicosanoid synthesis; fat digestion and 
absorption; alpha-linolenic acid metabolism; linoleic acid metabolism). PLA2G2A is 
an enzyme that hydrolyzes phospholipid species, liberating free fatty acids (most 
importantly arachidonic acid) and lysophospholipids. Arachidonic acid is the 
common precursor of the eicosanoids, a family of compounds with multiple roles in 
the inflammation process. 172 Interestingly, the protein has been found to be linked to 
T2DM 173, 174  and OA pathologies 175, 176,  but no comparison between OA/T2DM- 
and OA/T2DM+ groups has been performed so far. The relative intensities of 




Figure 4.2. Relative intensities of apolipoprotein A-1 and phospholipase A2 proteins in OA/T2DM- 
and OA/T2DM+ cohorts. Apolipoprotein A-1 protein has been found increased in the OA/T2DM-  
group (FC: 0.31) whereas phospholipase A2 protein has been found increased in the OA/T2DM+ 
group (FC: 1.9), (*adjusted p-value ≤ 0.05), (n=10). 
 
Heterogeneity in lipid and protein cartilage profiles associated with human osteoarthritis with or 
without type 2 diabetes mellitus 
64 
In addition to lipid metabolic pathways, the proteome analysis implicated other 
biological processes to be relevant. For instance, four pathways associated with 
cellular oxidative stress (oxidative stress; glutathione metabolism; oxidative 
phosphorylation; electron transport chain [OXPHOS system in mitochondria]) have 
been found increased in the OA/T2DM- group. This biological process is related to 
OA disease in the literature. 177-179 The oxidative stress reflects the imbalance between 
free radicals such as radical oxygen species (ROS) and antioxidants in the body, 
which can induce inflammatory responses and contribute to the pathophysiology of 
diseases. 180 Interestingly, the superoxide dismutase (SOD2) and the extracellular 
superoxide dismutase (SOD3) proteins are associated to these pathways. SOD2 and 
SOD3 represent two out of three members of the SOD family and are the most 
important line of antioxidant defense systems against the ROS. 181 In our case, we 
hypothesized that more ROS could be generated by the coexistence of both OA and 
T2DM diseases when compared to OA/T2DM- patients, which might be caused by a 
lower expression of both SOD2 and SOD3 in OA/T2DM+ patients.  
 
Moreover, to cellular oxidative stress pathways, Extracellular matrix (ECM) related 
pathways (osteoclast signaling; miR-509-3p alteration of YAP1/ECM axis; miRNA 
targets in ECM and membrane receptors; ECM-receptor interaction; focal adhesion) 
have been found enriched in the OA/T2DM- group. The degradation of ECM is 
known to be linked to the cartilage loss over the progression of OA pathology. In 
comparison, site-specific advanced glycation end-products (AGEs) modifications in 
the ECM proteins have been shown in T2DM disease. 182 Future studies applied on 
cartilage comparing both phenotypes and targeting specifically the ECM structure 
should be considered to investigate the key molecules associated to each disease. 
 
Five pathways related to organic compounds metabolism (pyrimidine metabolism 
and related diseases; urea cycle and metabolism of amino groups; methionine de 
novo and salvage pathway; beta-Alanine metabolism; glycine, serine, and threonine 
metabolism) have been found enriched in OA/T2DM+ patients. From these 
pathways, the organic compounds displayed have been associated with T2DM 183-185, 
but so far no studies investigated the complete role of these metabolites in the context 
of the disease. 
 
Lipid profile differences between OA phenotypes 
 
Since lipid regulation is one of the key factors in T2DM disease combined with the 
fact that several lipid metabolism-related proteins were altered between both OA 
phenotypes, spatially resolved MALDI-MSI experiments have been performed next. 
MALDI-MSI is a powerful method to investigate the biomolecular distribution of 
lipids through cartilage tissue sections. Especially, the technology applied on 
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cartilage enables the differentiation of the superficial layer and the deep layer of the 
cartilage, and provides spatial molecular information. 55, 160 This lipid content 
differences between the two layers have already been studied with another 
molecular imaging method called Time-of-Flight Secondary Ion Mass Spectrometry 
(TOF-SIMS). 56 However, this technology causes extensive fragmentation patterns in 
the mass spectra and need long acquisition times. 
 
The MALDI-MSI experiments followed by PCA-LDA analysis on 1354 spectra 
showed overall differences between OA/T2DM- and OA/T2DM+ patients based on 
their specific lipidomic profiles, with a PCA and DA variances of 38.1% and 1.15%, 
respectively. The projection of the discriminant function 1 (DF1) scores confirmed the 
lipid content differences between OA/T2DM- and OA/T2DM+ patients (figure 4.3A 
and table 4.4). Interestingly, more lysolipid species were found in OA/T2DM+ 
whereas sphingomyelin (SM) and phosphatidylcholine (PC) species were more 








































Table 4.4. Top 30 of the m/z and their corresponding loadings that differentiate the OA/T2DM- and 





MALDI-MSI experiments also revealed overall differences between deep and 
superficial layers of the cartilage tissues based on their specific lipidomic profiles. 
PCA followed by LDA was performed, resulting in variances of 38.2% and 8.2%, 
respectively. The projection of the DF1 scores (figure 4.4A and table 4.5) and the 
associated loading spectrum (figure 4.4B and table 4.5) confirmed the differences 
between superficial and deep layers.  
 
m/z Scaled loadings m/z Scaled loadings
725.57 1,50E+07 510.35 -8,22E+06
703.61 1,34E+07 496.34 -4,33E+06
676.80 8,69E+06 511.36 -3,17E+06
726.58 8,59E+06 536.35 -2,69E+06
704.62 8,39E+06 401.09 -2,61E+06
727.59 4,34E+06 524.36 -2,56E+06
760.60 3,64E+06 497.35 -2,52E+06
677.81 3,37E+06 482.33 -2,49E+06
782.56 2,76E+06 508.33 -1,97E+06
731.57 2,26E+06 529.21 -1,72E+06
705.56 2,23E+06 503.21 -1,57E+06
678.49 2,21E+06 440.23 -1,51E+06
810.65 2,19E+06 412.27 -1,40E+06
759.52 2,08E+06 515.20 -1,36E+06
753.59 2,08E+06 525.37 -1,36E+06
735.54 2,01E+06 532.31 -1,36E+06
761.61 2,00E+06 522.41 -1,34E+06
758.58 1,98E+06 505.23 -1,33E+06
786.60 1,98E+06 402.37 -1,30E+06
787.61 1,97E+06 512.31 -1,30E+06
783.57 1,93E+06 430.39 -1,24E+06
732.58 1,82E+06 400.08 -1,21E+06
788.62 1,73E+06 599.13 -1,16E+06
741.54 1,71E+06 476.20 -1,14E+06
784.58 1,64E+06 537.30 -1,12E+06
734.60 1,62E+06 530.22 -1,10E+06
589.23 1,57E+06 483.27 -1,07E+06
887.71 1,55E+06 504.22 -9,80E+05
704.02 1,53E+06 506.24 -9,55E+05
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Since MALDI-MSI preserves the spatial molecular information, a second PCA-LDA 
analysis was performed after manual annotation to compare the superficial and deep 
layers of both groups independently. These results showed that PCs and SMs species 
were characteristic of the superficial layers and more abundant in OA/T2DM- 
patients whereas lysolipid species were more characteristic of the deep layers and 
more present in the OA/T2DM+ cohort (Figure 4.5 and table 4.6).  
 
m/z Scaled loadings m/z Scaled loadings
703.61 2,38E+07 510.35 -1,07E+07
725.57 2,29E+07 522.41 -5,69E+06
760.60 2,28E+07 536.35 -4,68E+06
758.58 1,49E+07 482.33 -4,48E+06
786.60 1,49E+07 511.36 -4,39E+06
676.80 1,47E+07 508.33 -4,04E+06
704.62 1,38E+07 529.21 -2,82E+06
761.61 1,35E+07 523.35 -2,75E+06
782.56 1,33E+07 599.13 -2,64E+06
726.58 1,30E+07 532.31 -2,56E+06
734.60 1,30E+07 515.20 -2,49E+06
759.52 1,13E+07 512.31 -2,27E+06
787.61 1,06E+07 401.09 -2,25E+06
810.65 1,05E+07 476.20 -2,20E+06
788.62 9,25E+06 530.22 -2,15E+06
783.57 9,03E+06 537.30 -2,14E+06
784.58 8,90E+06 440.23 -1,97E+06
735.54 8,01E+06 483.27 -1,96E+06
808.63 6,23E+06 509.27 -1,93E+06
762.55 6,16E+06 503.21 -1,80E+06
811.66 6,10E+06 504.22 -1,77E+06
809.64 5,75E+06 477.08 -1,70E+06
732.58 5,55E+06 517.22 -1,68E+06
678.49 5,44E+06 543.22 -1,59E+06
677.81 5,34E+06 467.11 -1,59E+06
785.59 5,32E+06 468.18 -1,58E+06
727.59 5,17E+06 533.32 -1,57E+06
789.63 5,02E+06 505.23 -1,53E+06
756.56 4,67E+06 538.31 -1,52E+06
650.40 4,64E+06 431.14 -1,48E+06





























































Additional high spatial resolution MALDI-MSI was performed to confirm this 
differential lipid distribution through the cartilage. Experiments at 15 µm of lateral 
resolution followed by segmentation and pLSA analysis are in line with the previous 
data (Figure 4.6) with additional spatial information: transitional layers (represented 
by yellow and pink colors), lacunae (represented in light blue color) and chondrocyte 
cells (represented in blue color). 
 
m/z Scaled loadings m/z Scaled loadings m/z Scaled loadings m/z Scaled loadings
725.57 1,04E+07 496.34 -8,10E+05 725.57 3,30E+06 496.34 -7,90E+06
703.61 8,95E+06 524.36 -7,95E+05 726.58 1,80E+06 510.35 -7,68E+06
676.80 7,38E+06 650.40 -7,43E+05 703.61 1,54E+06 524.36 -5,28E+06
726.58 6,18E+06 525.37 -6,00E+05 704.62 1,16E+06 482.33 -4,03E+06
704.62 5,22E+06 622.31 -4,76E+05 943.75 1,14E+06 497.35 -3,83E+06
727.59 3,39E+06 529.21 -4,67E+05 881.71 1,09E+06 401.09 -3,06E+06
677.81 2,96E+06 402.37 -4,26E+05 887.71 1,09E+06 522.41 -2,98E+06
705.56 2,07E+06 497.35 -4,02E+05 915.73 8,74E+05 511.36 -2,71E+06
760.60 1,66E+06 430.39 -3,97E+05 882.72 8,65E+05 508.33 -2,48E+06
782.56 1,63E+06 503.21 -3,94E+05 676.80 8,12E+05 412.27 -2,37E+06
589.23 1,59E+06 510.35 -3,92E+05 727.59 8,02E+05 536.35 -2,36E+06
731.57 1,36E+06 515.20 -3,63E+05 944.70 7,93E+05 503.21 -2,26E+06
678.49 1,33E+06 651.41 -3,56E+05 917.69 7,93E+05 525.37 -1,98E+06
590.18 1,28E+06 403.32 -3,31E+05 916.68 7,76E+05 505.23 -1,82E+06
835.64 1,27E+06 652.15 -3,24E+05 913.71 7,15E+05 402.37 -1,58E+06
753.59 1,23E+06 428.37 -2,97E+05 888.72 6,46E+05 529.21 -1,52E+06
482.33 1,17E+06 440.23 -2,88E+05 741.54 6,31E+05 483.27 -1,51E+06
702.33 1,10E+06 506.24 -2,88E+05 941.73 6,20E+05 523.35 -1,48E+06
697.55 1,09E+06 623.32 -2,72E+05 879.69 5,90E+05 599.13 -1,40E+06
728.54 1,09E+06 505.23 -2,68E+05 753.59 5,70E+05 504.22 -1,38E+06
735.54 1,01E+06 456.26 -2,66E+05 914.65 5,45E+05 400.08 -1,37E+06
704.02 1,00E+06 550.36 -2,66E+05 945.71 5,32E+05 720.59 -1,33E+06
784.58 9,68E+05 526.32 -2,58E+05 889.66 5,30E+05 430.39 -1,32E+06
813.68 9,06E+05 426.22 -2,49E+05 971.71 5,27E+05 440.23 -1,32E+06
723.48 9,05E+05 517.22 -2,46E+05 901.65 5,25E+05 515.20 -1,16E+06
522.41 8,68E+05 624.19 -2,29E+05 973.73 5,13E+05 734.60 -1,10E+06
729.28 8,53E+05 530.22 -2,25E+05 907.72 5,07E+05 509.27 -1,08E+06
783.57 8,32E+05 476.20 -2,08E+05 883.67 4,98E+05 807.62 -1,06E+06
733.52 8,16E+05 498.29 -2,06E+05 677.81 4,95E+05 512.31 -1,01E+06
701.32 7,48E+05 638.41 -2,01E+05 918.70 4,88E+05 498.29 -9,92E+05
OA/T2DM- Patients OA/T2DM+ Patients OA/T2DM- Patients OA/T2DM+ Patients
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673.34 (N(CH3)₃ neutral loss)
184.00 (Phosphocholine)
716.50 (H₂O loss)
675.34 (N(CH₃)₃ neutral loss)
184.00 (Phosphocholine)
697.42 (N(CH3)₃ neutral loss)
573.50 (Headgroup neutral loss)
184.00 (Phosphocholine)
146.83 (Cyclophosphane + Na)
740.42 (H₂O loss)
699.42 (N(CH₃)₃ neutral loss)
575.50 (Headgroup neutral loss)
184.00 (Phosphocholine)
742.59 (H₂O loss)
701.42 (N(CH₃)₃ neutral loss)
577.42 (Headgroup neutral loss)
184.00 (Phosphocholine)
721.50 (N(CH3)₃ neutral loss)
597.50 (Headgroup neutral loss)
184.00 (Phosphocholine)
723.50 (N(CH₃)₃ neutral loss)
599.50 (Headgroup neutral loss)
577.33 (Headgroup (Na) neutral loss)
184.00 (Phosphocholine)
767.59 (H₂O loss)
726.50 (N(CH₃)₃ neutral loss)
602.50 (Headgroup neutral loss)
184.00 (Phosphocholine)
768.59 (H₂O loss)
727.50 (N(CH₃)₃ neutral loss)
184.00 (Phosphocholine)
769.67 (H₂O loss)
728.42 (N(CH₃)₃ neutral loss)
604.33 (Headgroup neutral loss)
184.00 (Phosphocholine)
770.67 (H₂O loss)
729.42 (N(CH₃)₃ neutral loss)
605.42 (Headgroup neutral loss)
184.00 (Phosphocholine)
747.50 (N(CH3)₃ neutral loss)
623.50 (Headgroup neutral loss)
184.00 (Phosphocholine)
685.50 (H₂O loss)
644.42 (N(CH₃)₃ neutral loss)
184.00 (Phosphocholine)
707.42 (H₂O loss)
666.42 (N(CH₃)₃ neutral loss)








782.56773 [PC 34:1+Na]⁺ 
785.65389 [SM 40:2;2+H]⁺
[PC 36:2+H]⁺





760.58559 [PC 34:1+H]⁺ 0.7
Precursor m/z MS/MS fragments Assignment ∆ppm error
0.9
734.56996
756.55189 [PC 32:0+Na]⁺ 0.8
806.56757 * [PC 36:3+Na]⁺ 0.4 Superficial layer
[SM 40:1;2+H]⁺ 0.8 Superficial layer
[PC 36:1+H]⁺ 0.9 Superficial layer
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In parallel to the targeted analysis, a DDA imaging approach has been also used to 
spatially resolve 19 other lipids at high-mass resolution which have never been 
found in the cartilage tissue yet (Table 4.8 and figure 4.7).  
 






672.42 (N(CH₃)₃ neutral loss)
184.00 (Phosphocholine)
694.50 (N(CH3)₃ neutral loss)









753.58865 * [SM 36:1;2+Na]⁺ 
0.7 OA/T2DM¯ patients[SM 36:1;2+H]⁺
[LPC 17:1+HCOO]¯ 0.4 OA/T2DM⁺ patients & Deep layer




























705.5896 [SM 34:0;2+H]⁺ 1.3
703.5739 [SM 34:1;2+H]⁺ 1.3
524.3703 [LPC 18:0+H]⁺ 1.5
520.3391 [LPC 18:2+H]⁺ 1.3
522.3546 [LPC 18:1+H]⁺ 1.5
496.3391 [LPC 16:0+H]⁺ 1.4
494.3234 [LPC 16:1+H]⁺ 1.4
468.3077 [LPC 14:0+H]⁺ 1.6



























734.5685 183.953 (Phosphocholine) [PC 32:0+H]⁺ 1.2
740.417 (H₂O loss)
699.364 (N(CH3)₃ neutral loss)
575.448 (Head group neutral loss)
183.959 (Phosphocholine)
759.6365 183.965 (Phosphocholine) [SM 38:1;2+H]⁺ 1.2
701.354 (N(CH3)₃ neutral loss)
183.965 (Phosphocholine)
726.483 (N(CH3)₃ neutral loss)
183.956 (Phosphocholine)
727.486 (N(CH3)₃ neutral loss)
183.956 (Phosphocholine)
787.6677 183.943 (Phosphocholine) [SM 40:1;2+H]⁺ 1.3




813.6833 [SM 42:2+H]⁺ 1.3
815.699 [SM 42:1+H]⁺ 1.3
785.6521 [SM 40:2;2+H]⁺ 1.3
786.5998 [PC 36:2+H]⁺ 1.2
760.5841 [PC 34:1+H]⁺ 1.3
758.5685 [PC 34:2+H]⁺ 1.3
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phospholipids in all mammalian cell membranes 189 whereas LPCs are lipids with 
pro-inflammatory properties produced under pathological conditions.190  
 
According to Zhang et al., the ratio between LPC and PC in the serum could be used 
to predict advanced knee OA.191 Indeed, the activation of the PC to LPC pathway 
seems to be associated with OA knee cartilage volume loss over time.175 Here, the 
higher level of LPC in OA/T2DM+ compared to OA/T2DM- condition could be 
linked to the co-existence of the two diseases, accentuating the inflammatory process 
and the view of the OA pathology as a systemic rather than a local pathology. This 
hypothesis is supported by studies showing an increased level of LPC in the plasma 
of diabetes patients 192 and the link between saturated fatty acids to insulin 
resistance.193 This insulin resistance can also be associated to the pancreatic secretion 
pathway found within the OA/T2DM+ group. 
 
Interestingly we also observed a higher abundance of PLA2G2A protein in the 
OA/T2DM+ group, which could be in line with the higher LPC content also 
associated with this group. Indeed, studies have found that PLA2G2A protein was 
enriched in the deep layer of the cartilage, which is supporting this hypothesis as 
LPCs species have been mainly localized in the same area.194, 195 We therefore 
postulated that the overexpression of PLA2G2A protein within the OA/T2DM+ 
cohort could explain an increased production of lysophospholipids in the deep layers 
of the cartilage tissue.  
 
PCs and SMs have been mainly detected in the superficial layer of the cartilage. 
Interestingly, a study conducted by Sarma et al. showed that these species were the 
major components of the lipid layer present at the surface of articular cartilage.196 
This specific localization of PCs and SMs species could also be linked to a different 
chondrocyte type/role in the superficial and the deep layers.197 Interestingly, SM 34:1 
is the most abundant SM species in synovial fluid (SF) and its level is elevated in OA 
and rheumatoid arthritis.198 This specie has been also found in chondrocyte cell 
pellets cultured in hypoxia condition (2.5% O2).51 
 
4.5. Chapter conclusions 
 
In this study, the main limitation remains the number of patients (n=20) and efforts 
should focus on the validation of these findings in a larger cohort. In addition, a 
small sample size restricts the possibility to correct for other biological parameters 
such as BMI, age or gender differences. Considering this last point, all patients from 
this study were over weighted or obese.  
Heterogeneity in lipid and protein cartilage profiles associated with human osteoarthritis with or 
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In summary, in this work we have provided a panel of distinctive proteins and lipids 
between OA/T2DM- and OA/T2DM+ phenotypes. Therefore, we clearly showed the 
need to consider knee OA as a complex disease that requires potentially different and 
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Sox9 determines translational capacity during early chondrogenic differentiation by regulating expression of 















































5. Sox9 determines translational capacity during early chondrogenic 
differentiation by regulating expression of ribosome biogenesis factors 




In our previous research, we found that in addition to the well-known extracellular 
matrix-related expression of Sox9, chondrogenic differentiation of progenitor cells is 
driven by a sharply defined bi-phasic expression of Sox9: an immediate early and a late 
(extracellular matrix associated) phase expression. The early phase Sox9 expression 
appeared to be essential in the initiation of chondrogenic differentiation and in this study, 
we aimed to determine what biological processes are driven by Sox9 during the early 
phase of chondrogenic differentiation.  
 
Sox9 expression in ATDC5 cells was knocked-down by siRNA transfection at the day 
before chondrogenic differentiation started or at day 6 in differentiation. Samples were 
harvested at 2 hours, and 7 days in differentiation. The transcriptome (RNA-seq) and 
proteome (label-free proteomics) were compared using pathway and network analyses. 
Total protein translational capacity was evaluated with the SuNSET assay, active 
ribosomes with polysome profiling and ribosome modus with bicistronic reporter assays. 
Early Sox9 knockdown severely inhibited chondrogenic differentiation weeks later. Sox9 
expression during the immediate early phase of ATDC5 chondrogenic differentiation 
regulates the expression of ribosome biogenesis factors and ribosomal protein subunits. To 
validate functional consequences of siSox9 treatment for ribosome function, we evaluated 
total translational capacity, polysome profiles and ribosome modus. Translational capacity 
was decreased by siSox9 treatment and this correlated to lower amounts of active mono- 
and polysomes. Finally, cap- versus IRES-mediated translation was altered by Sox9 
knockdown. 
 





Chondrogenesis, or chondrogenic differentiation, is the cellular process that describes the 
differentiation path of progenitor cells via early mesenchymal condensation into 
chondrocytes that synthesize a cartilage extracellular matrix (ECM). 199-201 Aside from 
articular cartilage formation and maintenance, skeletal development also depends on 
chondrogenic differentiation. Formation of the long bones of the mammalian skeleton 
depends on the activity of growth plates; cartilaginous entities at the ends of developing 
bones in which chondrocytes differentiate from progenitor cells. In contrast to articular 
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chondrocytes, differentiating growth plate chondrocytes are predestined to undergo 
hypertrophic differentiation and apoptosis. The remaining cartilage matrix is subsequently 
remodeled by osteoclastic/osteocytic activity, resulting in de novo synthesized bone.199-201 
In vivo, chondrogenic differentiation is almost exclusively initiated from local 
mesenchymal progenitor cells that reside in the cartilaginous tissue (growth plate resting 
zone202, articular cartilage superficial layer203) or in surrounding fibrous tissues (e.g. 
periosteum204, 205). In vitro however, chondrogenic differentiation has been reported from 
various primary (mesenchymal) progenitor cell sources including synovial 
fluid/membrane, bone marrow, adipose tissue and induced pluripotent stem cells. 206, 207 
In addition to high amounts of oligosaccharides (hyaluronic acid, heparan sulphate, 
chondroitin sulfate, etc.), important cartilage ECM proteins are type II collagen (Col2a1) 
and aggrecan (Acan).200, 208, 209 
 
The master regulator of chondrogenic differentiation is the transcription factor SRY (sex 
determining region Y)-box 9 (Sox9). Mutations in SOX9 were originally identified as the 
cause for campomelic dysplasia210, 211, a severe skeletal dysplasia associated with XY sex 
reversal and disproportionally short stature as well as general lack of cartilaginous tissue 
formation. SOX9 was found to be essential for murine early chondrogenic lineage 
determination.212 Upon nuclear translocation 213, 214, Sox9 binds as a homodimer to its 
consensus DNA recognition sequence (A/T)(A/T)CAA(A/T)G215, which includes the 
highly conserved AACAAT motif recognized by the HMG-box domain shared amongst 
Sox and Sry protein family members. In chondrogenic differentiation Sox9 drives the 
transcription of and cooperates with L-Sox5 and Sox6 for efficient transcription of the 
COL2A1 and ACAN genes.212, 216-219 Other ECM genes have also been shown to be under 
transcriptional control of Sox9; including COL9A1220, COL27A1221, and MATN1.222 223 
Besides L-Sox5 and Sox6, another important factor for Sox9-mediated transcription is 
Smad3, which modulates the interaction between Sox9 and CBP/p300224, thereby possibly 
explaining the pro-chondrogenic effect of BMPs and TGFβs on chondrogenic 
differentiation. 
 
During chondrogenic differentiation of progenitor cells in vitro, induction of Sox9 
expression is biphasic.225 In the first hours after initiation of chondrogenic differentiation 
Sox9 expression is transiently induced (immediate early Sox9 induction), together with the 
other members of the “Sox-trio”. Sox9 expression increases a second time in parallel with 
the synthesis of ECM molecules (late Sox9 induction). Previously, we showed that this 
immediate early Sox9 expression is in part regulated by the immediate early response 
gene 1 (Egr1)226 as well as by NFκB/p65.227 Similar expression patterns were also found in 
growth plate sections.227 The function of the early Sox9 induction itself remains elusive at 
present. In the present work we therefore determined the transcriptomic and proteomic 




differentiation, and uncovered the biological processes that are driven by Sox9 during the 
early phase of chondrogenic differentiation. 
 
5.3. Materials and methods 
 
ATDC5 cell culture 
 
ATDC5 cells (RIKKEN BRC, Japan)228 were cultured in a humidified atmosphere at 37°C 
and 5% CO2 in culture media consisting of Dulbecco’s Modified Eagle Medium 
(DMEM)/F12 (Life Technologies, MA, USA), 5% fetal calf serum (Life Technologies), 1% 
antibiotic/antimycotic (Life Technologies) and 1% non-essential amico acids (NEAA) (Life 
Technologies). ATDC5 cells provide a good model system to understand chondrogenic 
differentiation as they produced cartilage-specific proteoglycan and type II collagen. The 
Chondrogenic differentiation was induced by plating the cells in triplicates at 6.400 
cells/cm2, or 20.000 cells/cm2 in transfection experiments, and addition culture media 
with differentiation supplements 10 μg/ml insulin (Sigma-Aldrich, MO, USA), 10 μg/ml 
transferrin (Roche, Basel, Switzerland), and 30 nM sodium selenite (Sigma–Aldrich). 
Medium was refreshed every two days. A small interfering RNA (siRNA) duplex for Sox9 
(“Sox9 RNAi”) (sense: 5’-GACUCACAUCUCUCCUAAUTT-3’, anti-sense: 5’-
AUUAGGAGAGAUGUGAGUCTT-3’) and a scrambled siRNA duplex (“Control RNAi”, 
Eurogentec, Seraing, Belgium) were transfected (100 nM) one day prior to initiation of 
chondrogenic differentiation or at day 6 in differentiation using HiPerFECT according to 
manufacturers’ protocol (Qiagen, Hilden, Germany).  
    
RNA isolation  
 
RNA was isolated using TRIzol reagent (Life Technologies) and collecting the aqueous 
phase after centrifugation. RNA was precipitated with isopropanol (-80°C) and pellet by 
centrifugation. RNA pellets were washed in 80% ethanol and dried. RNA was dissolved in 
DNase/RNase-free pure water. RNA quantity and purity were determined 
spectrophotometrically (Biodrop, Isogen Life Sciences, Utrecht, The Netherlands). 
 
Quantitative real time PCR 
 
Total RNA was reverse transcribed to cDNA using standard procedures and random 
hexamer priming as previously described.229 Real-time quantitative PCR (RT-qPCR) was 
performed using Mesagreen qPCR master mix plus for SYBR Green (Eurogentec). A 
CFX96 Real-Time PCR Detection System (Biorad, CA, USA) was used for amplification: 
initial denaturation 95°C for 10 minutes, followed by 40 cycles of amplification 
(denaturing 15 seconds at 95°C and annealing 1 minute at 60°C). Validated primer 
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At indicated time points, plates were rinsed 3 times with 1% phosphate buffered saline 
(PBS). A mixture containing cOmplete Mini Protease Inhibitor Cocktail (Roche) in 25 mM 
ammonium bicarbonate (ABC) buffer (Sigma-Aldrich) and 6M urea (GE Healthcare, 
Eindhoven, The Netherlands) was added to the plates. Cells were collected by scraping 
with a rubber policeman and the samples were transferred to Eppendorf tubes. Triplicates 
were pooled and sonicated for 10 minutes and centrifuged at 12.000g for 10 min in 4°C. the 
supernatant containing proteins was finally transferred into new tubes and stored at -80° 
until further analysis. Bradford assay (Biorad) was performed to assess protein 
concentration. The concentrations were adjusted to 0.2µg/µL in order to normalize for the 
following steps. 
Samples were reduced with 20mM of DTT (Sigma-Aldrich) in 100 mM ABC for 45 min 
and alkylated with 40 mM of IAM (Sigma-Aldrich) in 100 mM ABC for 45 minutes in the 
dark. The alkylation step was stopped by adding 20 mM of DTT. Samples were then 
digested by a mixture of LysC and trypsin (Promega, Leiden, The Netherlands) added at a 
ratio of 1:25 (enzyme:protein) and incubated for 2h at 37°C in a water bath. Finally, 200 µL 
of 25 mM ABC buffer was added to the samples before overnight incubation at 37°C. The 
digestion was stopped by adding formic acid (FA) (Sigma-Aldrich) and acetonitrile 
(Biosolve, Valkenswaard, the Netherlands) at a final concentration of 1% and 2%, 
respectively. 
 
Label-free proteomics – Data acquisition and processing 
 
200 ng of each sample were injected in duplicate for liquid-chromatography mass 
spectrometry (LC-MSMS) analysis. The separation of the peptides was performed on a 
Thermo Fisher Scientific Dionex Ultimate 3000 Rapid Separation ultrahigh-performance 
liquid-chromatography (HPLC) system (Thermo Scientific, MA, USA) equipped with an 
Acclaim PepMap C18 analytical column (2µm, 75µm*150 mm, 100Å). The samples were 
first trapped on an online C18 column for desalting. The peptides were then separated on 
the analytical column with a 90-min linear gradient from 5% to 35% acetonitrile/0.1% FA 
and a flow rate set at 300 nL/min. The HPLC system was coupled to a high-mass 
resolution orbitrap MS Q-exactive instrument (Thermo Scientific). The mass spectrometer 
was operated in data-dependent acquisition (DDA) mode with the following settings: Full 
MS scan of the mass range m/z 350-1,650 at a resolution of 120,000 at m/z 400, followed by 
tandem mass spectrometry (MS/MS) scans for the fragmentation of the 15 most intense 
ions at a resolution of 30,000. The ions already selected for fragmentation were 
dynamically excluded for 20s. External calibration of the instrument was performed using 
a standard calibration solution for positive ion mode (Thermo Scientific). 
 
For protein identification, raw files were processed within the Proteome Discoverer 
software version 2.2 (Thermo Scientific) using the search engine Sequest with the Swiss-
Prot database Mus musculus version 2017-10-25 (TaxID 10090). The following parameters 
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were used for the database search: Carbamidomethylation of C for fixed modifications; 
oxidation of M and acetylation of protein N-term for variable modifications; trypsin for 
enzyme with a maximum of two missed cleavages; the precursor mass tolerance was set at 
10 ppm and the fragment tolerance at 0.02 Da; minimum and maximum peptide length of 
6 and 144 amino acids, respectively. Normalization of the data was performed on the total 
peptide amount. Percolator was used for the decoy database search and the FDR was fixed 
at 1% maximum. For protein quantitation, the Minora Feature Detector node in the 
processing step and the Feature Mapper node combined with the Precursor Ions 
Quantifier node in the consensus step were used with default settings. Finally, a list of 23 
commonly detected contaminants were removed manually (Table 5.2). 
 




Label-free proteomics – Data analysis 
 
ANOVA test and principal component analysis (PCA) were performed within the 
Proteome Discoverer software. ANOVA test was used to analyze the statistical 
significance of variation observed in protein abundance between the two conditions. PCA 
Protein ID Protein Name
Q8IUC1 Keratin-associated protein 11-1
P78385 Keratin, type II cuticular Hb3
A0A075B6S5 Immunoglobulin kappa variable 1-27
Q8N1N4 Keratin, type II cytoskeletal 78
P01859 Immunoglobulin heavy constant gamma 2
O95678 Keratin, type II cytoskeletal 75
P01860 Immunoglobulin heavy constant gamma 3
A0A0C4DH68 Immunoglobulin kappa variable 2-24
P48668 Keratin, type II cytoskeletal 6C
O76013-1 Keratin, type I cuticular Ha6
A0A0C4DH31 Immunoglobulin heavy variable 1-18
P01824 Immunoglobulin heavy variable 4-39
P0DOX5 Immunoglobulin gamma-1 heavy chain
P13645 Keratin, type I cytoskeletal 10
Q04695 Keratin, type I cytoskeletal 17
P68871 Hemoglobin subunit beta
P0DOX7 Immunoglobulin kappa light chain
P04264 Keratin, type II cytoskeletal 1
P35908 Keratin, type II cytoskeletal 2 epidermal
A0A0B4J1X5 Immunoglobulin heavy variable 3-74
P80748 Immunoglobulin lambda variable 3-21
P01614 Immunoglobulin kappa variable 2D-40




was performed on the abundance of all quantified protein to confirm and visualize the 
statistical significance of the protein abundance changes. The proteins were considered 
modulated with a p-value ≤ 0.05 and a fold change (FC) cut-off set at 2-fold. The 
modulated proteins were then imported within the EnrichR software 163 to display the top 
3 pathways of down or up-regulated proteins ranked by the combined score. 




Cells were lysed in RIPA buffer (150 mM NaCl, 1% NP-40, 0,5% Sodium deoxycholate, 
0,1% SDS, 50 mM Tris pH 8.0, 5.0 mM Ethylenediaminetetraacetic acid (EDTA) pH 8.0, 0.5 
mM dithiothreitol (DTT) supplemented with cOmplete Mini Protease Inhibitor Cocktail 
(Roche) and PhosSTOP phosphatase inhibitor (Sigma-Aldrich)). Extracts were sonicated 
and protein concentrations were determined with a bicinchoninic acid assay (BCA) assay 
(Sigma-Aldrich). Proteins were separated by SDS-PAGE and transferred to nitrocellulose 
membranes by electroblotting. Primary antibodies for immunodetection were anti-Sox9 
(Abcam, Cambridge, UK) and anti-Tubulin (Sigma-Aldrich). Bound primary anti-bodies 
were detected using immunoglobulins conjugated with HRP (DakoCytomation, Glostrup, 
Denmark) and visualized by enhanced chemoluminescence (ECL).   
 
sGAG assay  
The sulphated glycosaminoglycan (GAG) content was measured using a modified 
dimethyl methylene blue (DMB) assay.232 The absorbance of samples was read at 540 and 
595 nm using a spectrophotometer (Multiskan FC, Life Technologies) and GAG 
concentrations were calculated using a chondroitin sulfate standard curve (Sigma-Aldrich) 




Protein translational capacity of ATDC5 cultures (in sextuplicates) was assessed with the 
SUnSET assay.233, 234  5.4 µM puromycin (Sigma-Aldrich) was incubated for 15 minutes in 
the cell culture medium, immediately followed by washing in PBS and fixation for 20 
minutes with 10% formalin (VWR, Radnor, PA, USA). Permeabilization was performed for 
10 minutes with 0.1% Triton X-100. Wells were rinsed with PBS with 0.1% Tween (PBS-T) 
and blocked for 1.5 hour with 1% (m/v) skimmed milk powder (ELK, Campina, 
Zaltbommel, the Netherlands) in PBS-T, followed by overnight incubation at 4°C with the 
primary anti-puromycin antibody 12D10 (Sigma-Aldrich). After washing with PBS-T, 
wells were incubated for 1 hour at room temperature with the secondary goat anti-mouse 
Alexa488 antibody (Life Technologies). The fluorescent signal intensity was determined 
using a Tristar LB942 (Berthold, Bad Wildbad, Germany) equipped with excitation filter 
F485 and emission filter F353. Fluorescent data was normalized to DNA-content from the 
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same well.235 To this end, wells were washed with HEPES-Buffered Saline (HBS), followed 
by 1 hour incubation with 5 µg/mL DAPI (Life Technologies) plus 5 µg/mL HOECHST 
33342 (Life Technologies) in HBS. After subsequent washing steps with HBS, fluorescent 
signal intensity was determined using a Tristar LB942 (Berthold), using the excitation filter 




Polyosome fractionation was performed basically as described previously. 236 Three 15 cm 
plates with ATDC5 cells were used to generate a single sample. At the day of sample 
collection, cells were differentiated for 2 hours, then pre-treated for 5 minutes with 100 
µg/ml Cycloheximide (Sigma-Aldrich), washed twice in 0.9% NaCl with Cycloheximide 
and collected by scraping with a rubber policeman in cold 0.9% NaCl. Pelleted cells were 
lysed for 10 minutes in 1.8 ml polysome extraction buffer (20 mM Tris-HCl (pH7.5), 100 
mM KCl, 5 mM MgCl2, 0.5% Nonidet P-40, 100 µg/ml Cycloheximide, complete protease 
inhibitor cocktail (Roche) and RNasin (Promega, 40U/ml)) on ice. Nuclei and cellular 
debris were removed by centrifugation at 12.000x g for 10 minutes at 4C and 9/10th of 
the total volume was transferred to fresh tubes and measured spectrophotometrically 
(Nanodrop). Total yield was the same for siCtrl and siSox9 treated cells. Sucrose gradients 
(linear 10-50%) were made with the Gradient Master (BioComp, Fredericton, Canada) in 
ultracentrifuge tubes (Seton, SW41 tubes). Cytoplasmic extracts (250 µg/sample) were 
loaded to each gradient in a fixed volume (400 µl). Gradients were run on an ultra-
centrifuge (Beckman L60) at 39.000 rpm for 1.5 hours at 4C with max acceleration and 
deceleration 9. Samples were fractionated into 24 x 0.5 ml fractions using a Piston Gradient 
fractionator (BioComp) and fraction collector (Gilson FC203B, WI, USA) with continuous 
A260 monitoring. 
 
Bicistronic reporter assay 
 
Reporter constructs for the CrPv IGR IRES, the CrPv CCGG IGR IRES mutant, the HCV 
and the P53 IRES were a kind gift of Dr. S. Thompson. One day post plating, maxi-prep 
DNA (0.5 µg/well) and 100 nM siRNA were transfected into 24-wells wells (n=3/group) 
using Mirus Transit-X2 according to manufacturer’s instructions. The next day 
differentiation was induced for 24 hours, samples were collected by washing cells with 
0.9% NaCl and incubation in 100 µl passive lysis buffer for 15 minutes (Promega). 
Subsequently, samples were transferred to Eppendorf tubes and centrifuged for 10 
minutes at 12.000x g in a tabletop centrifuge. Next, 50 µl lysate was used for dual 
luciferase measurements (Promega) using a Berthold injection system (10 seconds 
counting time per cistron). Data is represented as fold change (FC) of the ratio Fluc/Rluc 





Statistics in other than proteomics or transcriptomic analysis 
Statistical significance was determined by two-tailed student t-tests using Graphpad 
PRISM 5.0 (Graphpad, CA, USA). Due to small sample size (n=3 samples) normal 
distribution of input data was assumed. Error bars in graphs represent mean ± standard 
error of the mean. Significance for all tests was set at p≤0.05. 
 
5.4. Results and discussion 
 
Early chondrogenic lineage commitment during mesenchymal condensation is driven by 
Sox9.212, 237, 238 Following lineage commitment, Sox9 is a key regulator of cartilage 
extracellular matrix (ECM) synthesis, by driving expression of ECM molecules like Acan, 
Col2a1 and others.212, 216-223 Sox9 also safeguards maintenance of cartilage homeostasis by 
influencing chondrocyte Nkx3-2 levels, a transcriptional repressor of chondrocyte 
hypertrophy.239, 240 This dual action of Sox9 is recapitulated in in vitro models of 
chondrogenic differentiation, as we have previously reported on bi-phasic expression 
dynamics of Sox9 in ATDC5 and BMSC chondrogenic differentiation.225, 226 In this earlier 
work we demonstrated that early (hours) transient induction of Sox9 expression by 
NFκB/p65 or Egr1 in ATDC5 chondrogenic differentiation is a prerequisite for late-stage 
(days) expression of cartilage ECM genes. As key transcription factor for cartilage, the vast 
majority of investigations on the downstream function of Sox9 have mainly focused on its 
role in the transcriptional regulation of cartilage ECM genes.212, 216-223 In addition, a 
function in epigenetic reprogramming has been suggested for early Sox9 226 , as well as a 
role for Sox9 in activating super-enhancers in chondrocyte cells.241 However, its 
downstream cell biological consequences during early chondrogenic differentiation are 
incompletely understood. The present study demonstrates that Sox9 expression during the 
early phase of ATDC5 chondrogenic differentiation regulates the expression of ribosomal 
protein subunits, as well as proteins that are involved in ribosome biogenesis that 
modulates ribosome activity and translation mode. These data, for the first time, connect 
the Sox9 transcription factor to regulation of protein translation during chondrogenic 
differentiation. 
 
Early Sox9 peak in ATDC5 chondrogenic differentiation 
 
During chondrogenic differentiation of progenitor cells in vitro, induction of Sox9 
expression is bi-phasic.225, 226 In the first (2-4) hours after initiation of chondrogenic 
differentiation of ATDC5 cells, Sox9 expression is transiently induced on mRNA (Figure 
5.1A) and protein level (Figure 5.1B). Sox9 expression increased a second time in 
differentiation around day 7 in differentiation (Figure 5.1A), in parallel with the 
expression of the important Sox9 transcriptional target Col2a1218 (Figure 5.1C) and 
glycosaminoglycan (GAG) content (Figure 5.1D).200, 216 The immediate early transient Sox9 
expression peak at 2 hours in differentiation does not correlate with the induction of 
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RNA expression and presented relative to t=0. Bars represent mean±SEM. ns= not significant, *=p<0.05, 
**=p<0.01, p=<0.0001. (C) Sox9 protein expression at t=2h (for “early knockdown condition) and t=7d (for 
“late” knockdown conditions) time point in Control and Sox9 RNAi conditions as measured by 
immunoblotting. αTubulin was used as loading control. Molecular weight markers (in kDa) are shown on 
the left. (D) Schematic representation of time points and comparisons for transcriptomics and proteomics 
analysis.  
 
The extracted RNA was used for RNA sequencing and Principal Component Analysis 
(PCA) confirmed that samples from control scrambled siRNA conditions at 2 hours and at 
7 days were separated from Sox9 siRNA knockdown samples at 2 hours and 7 days 



































Sox9 determines translational capacity during early chondrogenic differentiation by regulating expression of 




Noteworthy, the separation between the scrambled siRNA and Sox9 siRNA conditions 
was particularly evident at 2 hours, while separation between the scrambled siRNA and 
Sox9 siRNA conditions at 7 days was less obvious. At 2 hours in ATDC5 chondrogenic 
differentiation, knockdown of Sox9 induced the differential expression of 2422 genes, with 
1235 upregulated genes and 1187 downregulated genes (Figure 5.4A, B). At 7 days in 
differentiation 493 genes were differentially expressed due to knockdown of Sox9. From 
these differentially expressed genes, 203 genes were upregulated (only 15 overlapped with 
the 2 hours time point) and 290 genes were downregulated (49 genes overlapped with the 
2 hours condition) (Figure 5.4A, B). All genes that were differentially expressed (FC≥2; 
p<0.05) at 2 hours and at 7 days in ATDC5 chondrogenic differentiation following Sox9 
knockdown, are not shown in this thesis.  
 
Extracted protein samples from control conditions and Sox9 knockdown conditions at 2 
hours and 7 days in ATDC5 differentiation were used for LC MS/MS with label free 
quantification. PCA plotting confirmed that control samples at 2 hours clearly separated 
from the Sox9 knockdown samples at 2 hours in ATDC5 differentiation. In addition, and 
in concert with the PCA plot of the RNA sequencing data (Figure 5.3A), the separation 
between control and Sox9 knockdown conditions appeared to be most obvious at 2 hours 
in differentiation than at 7 days (Figure 5.3B). At 2 hours in differentiation, knockdown of 
Sox9 caused the differential expression of 90 proteins, with the expression of 29 proteins 
being upregulated and 61 proteins downregulated ((Figure 5.4C, D). At 7 days in 
differentiation, the knockdown of Sox9 induced differential expression of 19 proteins. Of 
these 19 proteins, the expression of 9 proteins was upregulated and 10 proteins were 
downregulated (p-value ≤ 0.05; FC cut-off set at 2-fold). There was no overlap between the 
Sox9-dependent differentially expressed proteins at 2 hours or at 7 days in differentiation 
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The proteins that were differentially expressed (FC≥2; p<0.05) at 2 hours and at 7 days in 
ATDC5 chondrogenic differentiation following Sox9 knockdown, are shown in tables 5.3 
and 5.4. 
 
Table 5.3. Significantly up and down-regulated proteins found in control siRNA compared to Sox9 RNAi 






Protein ID Gene name Protein Name Fold change p-value
Q99PG2-1 Ogfr opioid growth factor receptor 0.01 1.00E-17
Q80VJ2 Sra1 Steroid receptor RNA activator 1 0.01 1.00E-17
P23927 Cryab Alpha-crystallin B chain 0.24 7.41E-05
Q8K274 Fn3krp Ketosamine-3-kinase 0.25 8.66E-05
P63280 Ube2i SUMO-conjugating enzyme ubc9 0.28 4.86E-04
Q922W5 Pycr1 Pyrroline-5-carboxylate reductase 1, mitochondrial 0.30 9.65E-04
Q3UPH1 Prrc1 protein PRRC1 0.31 1.10E-03
Q9CZH3 Psmg3 Proteasome assembly chaperone 3 0.34 3.02E-03
Q571I9 Aldh16a1 Aldehyde dehydrogenase family 16 member A1 0.34 3.20E-03
P97346 Nxn nucleoredoxin 0.35 4.23E-03
P47964 Rpl36 60S ribosomal protein L36 0.35 4.39E-03
P62892 Rpl39 60S ribosomal protein L39 0.37 6.39E-03
Q91VR2 Atp5f1c ATP synthase subunit gamma, mitochondrial 0.37 6.67E-03
Q9CYG7 Tomm34 Mitochondrial import receptor subunit TOM34 0.38 9.11E-03
P61079 Ube2d3 Ubiquitin-conjugating enzyme E2 D3 0.39 9.56E-03
P21126 Ubl4a Ubiquitin-like protein 4A 0.39 1.09E-02
Q9D172 Gatd3a ES1 protein homolog, mitochondrial 0.39 1.11E-02
Q8K4L3-1 Svil Supervillin 0.40 1.20E-02
Q60932-1 Vdac1 voltage-dependent anion-selective channel protein 1 0.40 1.22E-02
Q920Q6-1 Msi2 RNA-binding protein Musashi homolog 2 0.40 1.23E-02
Q9CQQ7 Atp5pb ATP synthase F(0) complex subunit B1, mitochondrial 0.40 1.39E-02
Q9R0P3 Esd S-formylglutathione hydrolase 0.41 1.49E-02
O88696 Clpp ATP-dependent Clp protease proteolytic subunit, mitochondrial 0.41 1.49E-02
Q60931 Vdac3 Voltage-dependent anion-selective channel protein 3 0.41 1.51E-02
P50518 Atp6v1e1 V-type proton ATPase subunit E 1 0.41 1.58E-02
Q9JLV5 Cul3 Cullin-3 0.42 1.78E-02
P97765 Wbp2 WW domain-binding protein 2 0.42 1.79E-02
P51881 Slc25a5 ADP/ATP translocase 2 0.42 1.85E-02
P53995 Anapc1 anaphase-promoting complex subunit 1 0.42 1.91E-02
Q9CQS2 Nop10 H/ACA ribonucleoprotein complex subunit 3 0.42 2.01E-02
Q9CZ30-1 Ola1 obg-like ATPase 1 0.42 2.02E-02
Q99LS3 Psph phosphoserine phosphatase 0.42 2.02E-02
Q9DCA5 Brix1 Ribosome biogenesis protein BRX1 homolog 0.43 2.16E-02
Q32MW3 Acot10 Acyl-coenzyme A thioesterase 10, mitochondrial 0.43 2.34E-02
Q9D0I8 Mrto4 mRNA turnover protein 4 homolog 0.43 2.46E-02
P06151 Ldha L-lactate dehydrogenase A chain 0.43 2.51E-02
Q9DB20  Atp5po ATP synthase subunit O, mitochondrial 0.44 2.57E-02
Q9CQ65 Mtap S-methyl-5'-thioadenosine phosphorylase 0.44 2.62E-02
Q8BFR5 Tufm elongation factor Tu, mitochondrial 0.44 2.65E-02
Q9D7G0 Prps1 ribose-phosphate pyrophosphokinase 1 0.44 2.70E-02
Q80VD1 Fam98b Protein Fam98b 0.44 2.71E-02
Q8K4J6-1 Mrtfa MKL/myocardin-like protein 1 0.44 2.82E-02
Q6PER3 Mapre3 Microtubule-associated protein RP/EB family member 3 0.44 2.83E-02
Q9D0T1 Snu13 NHP2-like protein 1 0.44 3.01E-02
Q64105 Spr Sepiapterin reductase 0.45 3.04E-02
Q99JR5 Tinagl1 Tubulointerstitial nephritis antigen-like 0.45 3.06E-02
P35486 Pdha1 Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial 0.45 3.11E-02






Table 5.4. Significantly up and down-regulated proteins found in control siRNA compared to Sox9 RNAi 




Q61205 Pafah1b3 Platelet-activating factor acetylhydrolase IB subunit gamma 0.45 3.27E-02
Q3B7Z2 Osbp Oxysterol-binding protein 1 0.45 3.47E-02
P35979 Rpl12 60S ribosomal protein L12 0.46 3.61E-02
P70122 Sbds Ribosome maturation protein SBDS 0.46 3.62E-02
Q9D819 Ppa1 Inorganic pyrophosphatase 0.46 3.73E-02
Q9JLM8 Dclk1 serine/threonine-protein kinase DCLK1 0.46 3.76E-02
P62962 Pfn1 profilin-1 0.47 4.23E-02
O89023 Tpp1 Tripeptidyl-peptidase 1 0.47 4.27E-02
P48962 Slc25a4 ADP/ATP translocase 1 0.47 4.36E-02
Q9Z1R2 Bag6 Large proline-rich protein BAG6 0.47 4.49E-02
Q5FWK3 Arhgap1 rho GTPase-activating protein 1 0.47 4.64E-02
Q3V3R1 Mthfd1l Monofunctional C1-tetrahydrofolate synthase, mitochondrial 0.47 4.65E-02
Q9D0T2 Dusp12 Dual specificity protein phosphatase 12 0.47 4.82E-02
Q9WUU7 Ctsz Cathepsin Z 2.02 2.11E-02
P47739 Aldh3a1 Aldehyde dehydrogenase, dimeric NADP-preferring 2.02 2.08E-02
Q8C1M2 Znf428 Zinc finger protein 428 2.04 1.94E-02
Q9JJI8 Rpl38 60s ribosomal protein l38 2.06 1.78E-02
P18608 Hmgn1 Non-histone chromosomal protein HMG-14 2.12 1.42E-02
Q922U1 Prpf3 U4/U6 small nuclear ribonucleoprotein Prp3 2.13 1.38E-02
P62862 Fau 40S ribosomal protein S30 2.14 1.28E-02
Q6WKZ8-1 Ubr2 E3 ubiquitin-protein ligase UBR2 2.15 1.27E-02
O70326 Grem1 Gremlin-1 2.17 1.17E-02
Q9D9K3 Aven Cell death regulator Aven 2.19 1.10E-02
P43274 H1-4 Histone H1.4 2.19 1.07E-02
P15864 H1-2 Histone H1.2 2.24 8.91E-03
Q8R180 Ero1a ERO1-like protein alpha 2.24 8.79E-03
Q4KML4 Abracl Costars family protein ABRACL 2.26 8.33E-03
Q9CU62 Smc1a structural maintenance of chromosomes protein 1a 2.27 7.89E-03
Q8R0P4 Aamdc Mth938 domain-containing protein 2.28 7.75E-03
P43275 H1-1 Histone H1.1 2.28 7.60E-03
Q9CPY7-1 Lap3 cytosol aminopeptidase 2.33 6.20E-03
Q6NSR8 Npepl1 Probable aminopeptidase NPEPL1 2.34 6.13E-03
Q8C8T8 Tsr2 pre-rRNA-processing protein TSR2 homolog 2.36 5.56E-03
P43276 H1-5 Histone H1.5 2.37 5.45E-03
P63089 Ptn Pleiotrophin 2.38 5.28E-03
P09602 Hmgn2 Non-histone chromosomal protein HMG-17 2.57 2.51E-03
Q99JF8 Psip1 PC4 and SFRS1-interacting protein 2.89 7.55E-04
P62204 Calm Calmodulin 2.95 5.95E-04
Q9JHW4 Eefsec selenocysteine-specific elongation factor 3.17 2.74E-04
Q3SXD3 Hddc2 HD domain-containing protein 2 5.86 4.75E-08
Q9CY58-2 Serbp1 Isoform 2 of Plasminogen activator inhibitor 1 RNA-binding protein 6.88 2.96E-09
Q61164 Ctcf Transcriptional repressor CTCF 100.00 1.00E-17
Protein ID Gene name Protein Name Fold change p-value
Q9Z1E4 Gys1 glycogen [starch] synthase, muscle 0.01 1.00E-17
P21460 Cst3 Cystatin-C 0.31 7.10E-07
O54782 Man2b2 Epididymis-specific alpha-mannosidase 0.32 2.27E-05
P51660 Hsd17b4 peroxisomal multifunctional enzyme type 2 0.37 4.37E-13
Q99KV1 Dnajb11 DnaJ homolog subfamily B member 11 0.39 1.36E-09
Q9D125 Mrps25 28S ribosomal protein S25, mitochondrial 0.41 7.72E-08
Q60648 Gm2a Ganglioside GM2 activator 0.42 1.08E-07
Q9CQD1 Rab5a Ras-related protein Rab-5A 0.47 5.65E-03
Q99M71 Epdr1 Mammalian ependymin-related protein 1 0.47 1.64E-08
P24270 Cat catalase 0.48 9.68E-09
Q3TIV5-1 Zc3h15 Zinc finger CCCH domain-containing protein 15 2.11 3.46E-04
P35282 Rab21 Ras-related protein Rab-21 2.19 3.38E-03
Q9DCX2 Atp5pd ATP synthase subunit d, mitochondrial 2.26 1.17E-05
Q60996-1 Ppp2r5c Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform 2.29 7.93E-06
P45952 Acadm medium-chain specific acyl-CoA dehydrogenase, mitochondrial 2.30 3.83E-06
Q9CQX8 Mrps36 28S ribosomal protein S36, mitochondrial 2.37 1.16E-04
Q99JR5 Tinagl1 Tubulointerstitial nephritis antigen-like 2.75 1.37E-04
Q8BFS6-1 Cpped1 Serine/threonine-protein phosphatase CPPED1 3.06 2.14E-13
P84228 Hist1h3b histone H3.2 100.00 1.00E-17
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These data indicate that at 2 hours in chondrogenic differentiation the knockdown of Sox9 
induces different changes in the ATDC5 transcriptome and proteome when compared to 
knockdown of Sox9 at 7 days in differentiation. In addition, the consequences of Sox9 
siRNA treatment appears to be stronger at 2 hours than at 7 days of differentiation, as 
indicated by larger separation in the PCA plots and larger number of differentially 
expressed genes and proteins. The role of the immediate early Sox9 expression was further 
investigated by comparing the Sox9-dependent differentially expressed mRNAs and 
proteins at 2 hours in differentiation, since differences in mRNA expression are expected 
to reflect on differences in protein expression. Figure 5.4E and F shows 4 overlapping 
mRNAs and proteins upregulated in the early Sox9 knockdown condition (Rps30/Fau, 
Avan, Eefsec, Rpl38) and 3 overlapping mRNAs and proteins downregulated in the early 
Sox9 knockdown condition (Ube2d3, Dclk1, Svil).  
 
Immediate early Sox9 expression is involved in ribosomal protein expression 
 
To determine which prominent pathways link to the Sox9-dependent differential 
transcriptome and proteome at 2 hours in differentiation, we performed pathway 
analyses. Both WikiPathways and KEGG Pathway analysis revealed that “Cytoplasmic 
Ribosomal Proteins” and “Ribosome” pathways were in the top three of identified 
enriched pathways (Table 5.5).  
 
Table 5.5. Early Sox9 expression is involved in ribosomal pathways. Top 3 identified enriched pathways 
from WikiPathways 2019 and KEGG2019 pathway analysis in control RNAi compared to Sox9 RNAi at 2 























Such strong overrepresentation of the “Cytoplasmic Ribosomal Proteins” and “Ribosome” 
pathways was not obvious in the Sox9-dependent differential transcriptome and proteome 
at day 7 in differentiation (Table 5.6). 
 
Table 5.6. Top 3 identified enriched pathways from WikiPathways 2019 and KEGG2019 pathway analysis 
in control siRNA compared to Sox9 RNAi at 7 days condition in ATDC5 differentiation for transcriptome 













Pathway ID Pathway description P-value (p) Combined score
WP163 Cytoplasmic Ribosomal Proteins 3.67E-11 77.64
WP1248 Oxidative phosphorylation 3.86E-07 45.24
WP295 Electron Transport Chain 2.74E-07 38.77




Pathway ID Pathway description P-value (p) Combined score
WP163 Cytoplasmic Ribosomal Proteins 5.96E-05 117.49
WP175 Acetylcholine Synthesis 3.11E-02 110.19
WP298 G13 Signaling Pathway 1.33E-02 49.21




Name Adjusted p-value (q)
Glycolysis / Gluconeogenesis 5.20E-01
Pyruvate metabolism 3.49E-01
5.86E-01





WikiPathways database (Mouse) - Proteome (2h condition)
Name Adjusted p-value (q)
Ribosome 3.39E-08
Huntington disease 1.90E-06
KEGG database (Mouse) - Transcriptome (2h condition)
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Further analysis of the 2 hours Sox9-dependent transcriptome datasets revealed the 
differential expression of 29 ribosomal proteins from the large (60S) ribosomal subunit 
(Rpls) and 10 ribosomal proteins from the small (40S) ribosomal subunit (Rpss) in the Sox9 
knockdown condition at 2 hours in differentiation (Figure 5.5A). In addition, the 2 hours 
proteomics datasets demonstrated the differential expression of 5 ribosomal Rpl and Rps 
proteins (Figure 5.5A and table 5.2). Notably, the 4 overlapping mRNAs and proteins 
(Rps30/Fau, Avan, Eefsec, Rpl38) that were found to be upregulated in the Sox9 
knockdown condition at 2 hours in ATDC5 chondrogenic differentiation (Figure 5.4E) are 
all linked to protein translation and represent either ribosomal protein subunits or factors 
with a known function in ribosome biogenesis. Additional factors involved in ribosome 
biogenesis, but only differentially expressed in either the 2 hours transcriptomics or 
proteomics datasets were SBDS, Nop10 and Brix1 (Data not shown). Since ribosomes 
consist of protein and ribosomal RNA (rRNA), we next investigated by RT-qPCR whether 
rRNA levels are also affected by the Sox9 knockdown at 2 hours in differentiation in 
ATDC5. Expression of 18S rRNA, 28S rRNA and 5.8S rRNA was not significantly different 
between the conditions (Figure 5.5B). Together, these data indicate that the immediate 
early Sox9 expression during ATDC5 chondrogenic differentiation is involved in 
ribosomal protein expression and ribosome biogenesis.  
 
Pathway ID Pathway description P-value (p) Combined score
WP1253 Type II interferon signaling (IFNG) 3.13E-10 287.23
WP163 Cytoplasmic Ribosomal Proteins 8.22E-10 147.60
WP222 Cytokines and Inflammatory Response 4.08E-03 33.06




Pathway ID Pathway description P-value (p) Combined score
WP2318 Fatty acid oxidation 9.46E-03 490.58
WP317 Glycogen Metabolism 4.71E-04 474.34
WP55 Steroid Biosynthesis 1.32E-02 325.25




Primary bile acid biosynthesis 1
Amyotrophic lateral sclerosis (ALS) 3.34E-01




KEGG database (Mouse) - Proteome (7d condition)
Name Adjusted p-value (q)
Measles 1.75E-06
WikiPathways database (Mouse) - Proteome (7d condition)
Adjusted p-value (q)
Name Adjusted p-value (q)
Epstein-Barr virus infection 1.52E-08
Herpes simplex virus 1 infection     2.28E-10
WikiPathways database (Mouse) - Transcriptome (7d condition)
Adjusted p-value (q)
5.51E-08
   7.23E-08
1.44E-01
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particularly susceptible for disturbances in ribosome protein translation activity. Indeed, 
during chondrogenesis, a large amount of proteinaceous cartilage ECM is produced by the 
developing growth plate and disturbances in ribosome activity are likely to impair ECM 
synthesis, with consequences for the development of skeletal elements. It should however 
be noted that the link between Sox9 and chondrocyte translation activity in the present 
work was particularly present during early differentiation rather than late differentiation. 
This is highlighted by deregulated expression of ribosomal subunits following Sox9 
knockdown in early ATDC5 chondrogenic differentiation (Figure 5.5 and table 5.4). In 
addition, the knockdown of Sox9 specifically impacted total protein translation 
throughout differentiation when knocked-down early, while not having an effect on 
protein translation when knocked-down during late chondrogenic differentiation (Figure 
5.6). The link between early Sox9 and chondrocyte protein translation suggests that 
protein translation is likely to be paced through Sox9 during early chondrogenic 
differentiation However, it remains to be determined how early Sox9 is specifically able to 
influence chondrocyte translational capacity. Our present data suggest that expression of 
ribosomal protein subunits, ribosome biogenesis factors and ancillary ribosomal factors 
(such as IRES trans-acting factors (ITAFs)) depends on Sox9 during early chondrogenic 
differentiation, with downstream consequences for translation in the later differentiation 
program. Since we found these ribosomal genes and proteins differentially expressed after 
Sox9 knockdown, we studied supplemental data of previously published Sox9 ChIP-seq 
and Sox9-/- mouse studies.238, 241 In supplementary data of a Sox9 ChIP-seq study we found 
24 Rps and Rpl genes that were enriched in Sox9 occupancy and 14 with Sox6 occupancy 
of which 10 overlapped.241 Notably, this included Rpl38, which we found to be 
differentially expressed at the mRNA and protein level in our Sox9 knockdown condition.  
 
Aside from ribosome core components, we found differential expression of several factors 
regulating the mode of protein translation. The rate-limiting step of cap-mediated 
translation is eukaryotic initiation factor 4. Interestingly, EIF4BP2 was downregulated at 
the protein level at 2 hours of differentiation in Sox9 knockdown cells. EIF4 binding 
proteins were shown to regulate cell proliferation, but not cell size.246 Unexpectedly, we 
found strong differences in IRES activity upon early Sox9 knockdown after 24 hours of 
differentiation. Of note, the CrPv IGR IRES (Type IV) does not require ITAFs and is able to 
recruit the ribosome directly.247 The activity of this IRES was increased and might be 
regulated by specific Rps/Rpls that transiently interact with the core ribosome 
components. The HCV (Type III) and P53 IRES do require additional ITAF co-factors.248 
Based on the increased expression of the ITAF Rpl38, it is tempting to speculate that other 
ITAFs that facilitate HCV/P53 IRES translation are down regulated and may contribute to 
alternative use of ribosome translation modus. Rpl10a, Rpl11, Rpl38 and Pdcd4 were 
shown to regulate IRES-mediated translation.248 Rpl10a is known to activate the IGF2, 
APP, Chmp2A and Bcl-2 IRES. Gain and loss of function studies in the fruit fly showed that 




preferentially translated by a subpool of ribosomes in embryonic stem cells that required 
ribosome-associated Rpl10a protein.250 Insulin and IGF1 signaling are crucial for ATDC5 
differentiation228 Rpl11 induced the BAG1, CSDE1 and LamB1 IRESes, while Rpl38 
activated a Hox gene IRES. Up regulation of Rpl11 led to stabilization of P53 and reduced 
proliferation of breast cancer cell-lines.251 In contrast, we found a reduction in P53 IRES 
activity. Of note, P53 and ribosome biogenesis were recently coupled through SBDS.252 In 
our dataset, SBDS was down regulated at the protein level at 2 hours in differentiation in 
siSox9 treated cells, which matches with the observed reduction in ribosomes and/or 
ribosome activity. Pdcd4 activated or inhibited the P53, INR, IGF1R, BcL-XL and XIAP 
IRESes.248 The IGF1R IRES might again be relevant for the ATDC5 differentiation model. 
Finally, Rpl38 was the only ITAF that was found to be up regulated at both the mRNA and 
protein level. It was found to control HOX gene translation during murine embryonic 
development 253 and knockout led to ectopic mineralization in certain soft tissues.254 
 
Together we identified multiple connections between immediate early Sox9 expression in 
ATDC5 chondrogenic differentiation and downstream consequences for expression of 
ribosomal protein subunits, ribosome biogenesis factors and ITAFs. This connection 
between Sox9 expression and protein translation appears to be centered in early 
chondrogenic differentiation with consequences for protein translation in later stages. This 
suggests a role for early Sox9 in the priming of the progenitor cell in the chondrogenic 
differentiation program for cartilaginous ECM production later in differentiation. This 
provides a new level of understanding how Sox9 controls the fate of chondrogenic 
differentiation at the level of protein synthesis. In this respect it is tempting to speculate on 
the classification of campomelic dysplasia 255, as links between Sox9 and genes involved in 
ribosomopathies 245, 256 were identified in the present work (SBDS, Rpl11, Rps26). 
 
5.5. Chapter conclusions 
 
In conclusion, we here collected essential new data on the regulation by Sox9 during early 
chondrogenic differentiation, uncovering an unanticipated role of Sox9 in ribosome 
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OA is becoming more prevalent as the world population ages. In 2032, at least an 
additional 26 thousand of people per one million population older than 45 years are 
estimated to have consulted for OA in a peripheral joint compared to 2012.257 This 
increase in OA leads to challenges for health care and public health systems. We 
need to address this problem with new, personalized treatments. 
 
One of the main goals of this thesis is to employ MS-based approaches on human 
knee cartilage to help for the classification of different OA phenotypes.  
 
A multimodal approach can improve the classification of phenotypes 
 
The importance and need to consider different OA phenotypes have been extensively 
discussed in this thesis and described in the literature. Deciphering the biomolecular 
profiles of each OA phenotype will improve the classification models as well as the 
development, design, and efficacy of OA-phenotype-specific drugs. Combined with 
physician-advised and preventive lifestyle choices (healthy lifestyle, low-impact 
exercise, healthy diet…), the research and approach discussed in this thesis will 
ultimately improve patient care and have an effect on general health outcomes. 
 
In this thesis, the combination of MALDI-MSI and bottom-up proteomic approaches 
is described as a powerful methodology to study the knee cartilage tissue and 
improve the classification of two different OA phenotypes. The protocol presented 
herein enabled us to discover inflammatory proteins and lipids associated to either 
OA or T2DM disease. Although our results need further investigation through 
functional studies, this fundamental knowledge is the first step towards new 
pharmaceutical interventions. Importantly, the same protocol we used could also be 
considered to classify i) other OA phenotypes described in the literature or ii) OA 
patients based on other variables such as gender, age, post-traumatic vs non-post- 
traumatic, or BMI. For this last purpose, the access to patient´s clinical history 
remains crucial. 
 
Additionally, the cross-tissue data collected at different areas from the joint of the 
same patients could also improve the classification of OA phenotypes. Indeed, the 
approach presented could be reproduced in other tissues involved in the OA disease, 
such as Hoffa’s fat pad, bone or synovium membrane. As a consequence, the 
complementary biological information obtained on such tissues could significantly 
improve or validate the data from the study described in chapter 4. 
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The experimental design as a new methodology to optimize a MALDI-MSI 
approach 
 
The optimization of methodologies is also an essential factor to be considered in all 
scientific fields. In this thesis we described a new strategy to optimize the MALDI-
MSI protocols for the detection of endogenous metabolites in cartilage tissues. Our 
experimental design revealed the most important parameters for method 
optimization and consequently improved the quality of MSI data. This optimized 
workflow could then be further used to either investigate the metabolic changes of 
different OA-phenotypes or on cartilage tissues displaying another pathology such 
as the rheumatoid arthritis disease. 
 
Our experimental design methodology could also be considered in any scientific field 
where optimized protocols are needed. As an example, the use of the experimental 
design could be useful to create standard operating protocols (SOP) within research 
laboratories. 
 
The heat stabilization process improves the detection of fast-degrading 
compounds and other biomolecules 
 
Tissue degradation starts when a tissue is removed from its native environment. 
Alteration at the molecular level can occur within seconds. In a biological project 
involving a large cohort of patients, tissue degradation could lead to inter-sample 
variation, incorrect data interpretation, and misleading conclusions. In this thesis, the 
heat stabilization process was performed immediately before the snap-freezing 
process of the cartilage tissues. This heat stabilization process may prevent artificial 
biological changes and ensure accurate downstream MALDI-MSI results. The 
implementation of this process into pharmaceutical companies’ workflows could 
help companies to assess the abundance of analytes in their products. 
 
The suggested stratification of OA patients and the MALDI-MSI developments 
presented in the thesis can be predominantly applied in biomedical studies and 
health care fields. The identified lipidomic and proteomic markers for improved 
stratification of OA phenotypes can be used for personalized therapies but could also 
be investigated as potential biomarkers for diagnosis of OA disease. Moreover, our 
studies revealed the possibility to rapidly process and prevent biological changes 
(e.g. degradation) of clinical knee cartilage samples. Our heat stabilization process 
should also be considered in every clinical study, where MSI is needed as a 




The project also initiated a strong collaboration between scientists and clinicians 




















































































7. General discussion 
 
Mass spectrometry imaging (MSI) has generated enormous momentum over the past 
decade. MSI covers a wide range of biomedical applications such as biomarker 
discovery and tissue classification. MALDI-MSI remains the most applied MSI 
technique in the rheumatology field.  
 
In this thesis, we developed and optimized MALDI-MSI methods for studying 
cartilage and deployed several -omics approaches to decipher OA disease at a 
molecular level. 
 
7.1. Sample preparation 
 
Sample preparation is one of the most critical steps in analytical chemistry. Chapter 3 
demonstrates that the detection of endogenous metabolites in human cartilage by 
MALDI-MSI would not be possible without an optimized workflow, from sampling 
to data analysis. In particular, the combination of the Denator system and the design-
of-experiments approach has enabled better detection of metabolites in cartilage. 
When properly applied, the Denator system immediately and permanently prevents 
biological changes, and therefore allows samples to reflect the in vivo state as closely 
as possible. The Denator system was also used in chapter 4, as we demonstrated its 
efficiency to preserve endogenous lipid species. The design-of-experiments concept 
has a great potential to reduce the number of experiments and to provide the most 
significant parameters for high quality results. The workflow presented here could 
be applied to any other biomolecular class and could be considered before dealing 
with precious samples.  
 
Additional sample preparation steps were also developed for dealing with difficult 
tissue types, such as articular cartilage. Articular cartilage is difficult to work with for 
several reasons. First, the amount of cartilage tissue obtained after the knee surgery 
differs from patient to patient. This is mainly due to the different OA grades, which 
reflects the severity of the disease. Moreover, articular cartilage tissue is negatively 
charged and thus tends to detach from the slide or sample holder when using high 
pressure mass spectrometers. Different solutions have been implemented to 
overcome these weak points. The use of 8mm punches was a method introduced to 
standardize the sample collection and ensure the collection of the different cartilage 
layers. Double-sided copper tape was applied to slides before the thaw mounting of 
cartilage tissues. The use of double-sided copper tape was a simple way to avoid 
adhesion trouble. However, the use of double-sided copper tape compromised the 
optical visualization of any staining protocol performed after the MALDI-MSI. A 
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more optimal solution that allows for optical visualization and staining and also 
prevents cartilage tissue sample adhesion problems needs to be developed. 
 
7.2. The need of a multimodal approach 
 
Bottom-up proteomics is a mass spectrometry-based methodology that was used in 
the research conducted in chapters 4 and 5. The main goal of bottom-up proteomics 
is to identify and quantify proteins across different samples. The workflow for 
bottom-up proteomics is well established in the proteomic community, but sample 
preparation can differ slightly between applications. In this thesis, the sample 
preparation of articular cartilage (chapter 4) is different from the one used for 
ATDC5 cells (chapter 5). More importantly, both sample preparation techniques 
highlight the necessity to combine the bottom-up, label free proteomics approach 
with other techniques to have a more complete understanding of the biological 
processes. The workflow used in chapter 4 combined the bottom-up approach with 
MALDI-MSI for lipid analysis. The workflow results in a specific panel of distinctive 
proteins and lipids between OA/T2DM- and OA/T2DM+ phenotypes that need to be 
validated in a larger cohort. The work presented in chapter 5 combined label free 
proteomics with transcriptomics and revealed that the ribosomal protein synthesis 
system is regulated by Sox9 gene expression during early chondrogenic 
differentiation of ATDC5 cells.  
 
7.3. Molecular phenotypes of OA 
 
OA is a heterogeneous disease with multiple molecular phenotypes. The 
classification of these phenotypes could drastically transform clinical trials and 
improve their efficiency. The classification also supposes the need to access patient 
clinical history as much as possible. In chapter 4, we showed the possibility to 
classify OA/T2DM- from OA/T2DM+ patients based on relevant metabolic 
pathways such as lipid regulation. Interestingly, the other pathways described in 
chapter 4, such as cellular oxidative stress or extracellular matrix (ECM) pathways, 
could also be considered for future studies. Another future direction is to compare 
more OA-related disease classification parameters than just OA/T2DM- to 
OA/T2DM+. For instance, BMI based classification, age, or gender might result in 
the discovery of other molecules of interest. Moreover, OA subclassification in 
relation to the other diseases linked to the MetS phenotype, previously described in 
the introduction, could reveal additional and more specific molecular markers. As an 
example, classification of OA/dyslipidemia- and OA/dyslipidemia+ phenotypes 
could be considered. As an additional note, in chapter 4, ten patients were used per 
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group, but validation of potential prognostic and diagnostic markers should be 
evaluated in a larger cohort. 
 
7.4. Perspective of MSI in the OA field 
 
The results in chapter 2 demonstrated the potential of the imaging technologies and 
their applications in the OA field. We showed how MSI, LESA and LMD could be 
applied to spatially resolve the proteins on cartilage tissue but more importantly, all 
the approaches described could also be used to investigate other biomolecules 
(lipids, metabolites or glycans, for instance). Moreover, chapter 2 showed that 
enzymes other than trypsin, the gold standard for peptide analysis, can be used in 
some applications in the OA field. This is the case for the collagenase family, which 
could be used to improve the protein coverage of MS-based experiments. The 
combination of different enzymes could also be considered to improve protein 
















































In chapter 2, we reviewed different proteomic approaches and their applications in 
the OA field. The chapter also highlighted the recent imaging technologies, such as 
MSI, LESA, and LMD, which are not yet fully applied by the OA community. The 
advantages, disadvantages, and recent applications of MSI, LESA, and LMD are 
described in chapter 2. Mass cytometry and multiplexed ion beam imaging are also 
presented as spatially-resolved approaches to consider for targeted analyses.  
 
An optimized MALDI-MSI approach for the detection of endogenous metabolites in 
human OA cartilage is described in chapter 3. In particular, we demonstrated the 
importance of heat stabilization to preserve the endogenous metabolites and lipids 
within the cartilage samples. We showed the potential of a design-of-experiments 
approach to optimize the spraying step. This design-of-experiments approach also 
revealed how small changes can drastically improve or reduce the data quality. 
Finally, the validation of the optimized MALDI-MSI approach was performed using 
a high mass resolution instrument and showed higher metabolic activity in the 
superficial layer of the cartilage.  
 
In chapter 4, the MALDI-MSI technology for lipid analysis was combined with a 
label-free proteomics approach to reveal different molecular cartilage profiles 
between OA/T2DM- and OA/T2DM+ phenotypes. Our work showcased specific 
lipids associated to each phenotype as well as differences in phospholipid content 
between superficial and deep layers of the cartilage. We also highlighted the need to 
examine apolipoprotein A-1 and phospholipase A2 in a larger cohort study as well as 
for further functional analysis.  
 
In chapter 5, we combined label-free proteomics and transcriptomics to uncover a 
potential new role of Sox9 gene, known to be involved in the chondrogenesis 
process. We proposed new functions of Sox9 during early chondrogenic 
differentiation and showed its implication in ribosomal translation as well as in the 
protein translation capacity. Our data also suggest a role for early Sox9 expression in 
the priming of the progenitor cells in the chondrogenic differentiation program for 
cartilaginous ECM. 
 
The valorization of this thesis is presented in chapter 6. The need to consider a 
multimodal approach to improve the classification of phenotypes is highlighted. 
Then, the design of experiments is described as a new strategy to optimize a MALDI-
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MSI approach.  Finally, we showcased the heat stabilization process for the 




In hoofdstuk 2 bespreken we verschillende proteomische benaderingen en hun 
toepassingen in het OA-veld. Ook belicht dit hoofdstuk de recente beeldvormende 
technologieën, zoals MSI, LESA en LMD, die nog relatief onbekend zijn binnen de 
OA-gemeenschap. Daarnaast worden de voordelen, nadelen en recente toepassingen 
van MSI, LESA en LMD beschreven. Ten slotte worden massacytometrie en 
gemultiplexte ionenbundelbeeldvorming gepresenteerd als ruimtelijk opgeloste 
benaderingen voor gerichte analyses. 
 
Een geoptimaliseerde MALDI-MSI methode voor de detectie van endogene 
metabolieten van artrose in humaan kraakbeen wordt beschreven in hoofdstuk 3. In 
het bijzonder hebben we het belang aangetoond van warmtestabilisatie om de 
endogene metabolieten en lipiden in de kraakbeenmonsters te behouden. Ook lieten 
we de potentie zien van een experimenteel ontwerp methodiek om de stabilisatiestap 
te optimaliseren. Deze aanpak liet ook zien hoe kleine veranderingen de 
datakwaliteit drastisch kunnen verbeteren of verminderen. Tenslotte werd de 
geoptimaliseerde MALDI-MSI methode gevalideerd met behulp van een instrument 
met hoge massa resolutie en vertoonde een hogere metabolische activiteit in de 
oppervlakkige laag van het kraakbeen.  
 
In hoofdstuk 4 werd de MALDI-MSI technologie toegepast voor lipidenanalyse en 
gecombineerd met labelvrije proteoom analyses om de verschillende moleculaire 
kraakbeenprofielen van OA/T2DM- en OA/T2DM+ fenotypes te onthullen. Ons 
werk toonde specifieke lipiden geassocieerd met elk fenotype, evenals verschillen in 
fosfolipidengehaltes tussen oppervlakkige en diepe lagen van het kraakbeen. We 
benadrukten ook de noodzaak om apolipoproteïne A1 en fosfolipase A2 te 
onderzoeken in een grotere cohortstudie en voor verdere functionele analyse. 
 
In hoofdstuk 5 hebben we labelvrije proteomics en transcriptomics gecombineerd 
om een mogelijke nieuwe rol van het SOX9 gen te ontdekken, waarvan bekend is dat 
het betrokken is bij het chondrogenese proces. We wezen op een nieuwe functie van 
het SOX9 gen tijdens vroege stadia van chondrogene differentiatie en toonden de 
betrokkenheid bij zowel ribosomale translatie als bij het translatievermogen van 
eiwitten. Onze gegevens suggereren ook een rol voor vroege SOX9 bij de priming 
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van de voorlopercellen in het chrondogene differentiatieproces voor 
kraakbeenachtige ECM. 
 
De valorisatie van dit proefschrift wordt gepresenteerd in hoofdstuk 6. Hier wordt 
de noodzaak om een multimodale aanpak te overwegen om de classificatie van 
fenotypes te verbeteren benadrukt. Vervolgens wordt het ontwerp van de 
experimenten beschreven als een nieuwe strategie om een MALDI-MSI methode te 
optimaliseren. Ten slotte hebben we het warmtestabilisatie proces gedemonstreerd 
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